

# Subject Index—Volume 98

No. 1, July 1, pp. 1-214  
 No. 2, July 15, pp. 215-436  
 No. 3, August 1, pp. 437-660  
 No. 4, August 15, pp. 661-884  
 No. 5, September 1, pp. 885-1104  
 No. 6, September 15, pp. 1105-1330  
 No. 7, October 1, pp. 1331-1554

No. 8, October 15, pp. 1555-1778  
 No. 9, November 1, pp. 1779-2000  
 No. 9, November 1, Supplement, pp. 2001-2082  
 No. 10, November 15, pp. 2083-2306  
 No. 11, December 1, pp. 2307-2538  
 No. 12, December 15, pp. 2539-2742

## A

- Acquired immunodeficiency syndrome  
   Burkitt lymphoma in, chemotherapy for, 1196  
   Hodgkin disease in, population-based patterns of, 300  
   Kaposi sarcoma in, highly active antiretroviral therapy and, 2440  
 Acute leukemia. *See* Leukemia  
 Adenocarcinoma. *See also* specific sites and types  
   DARPP-32 in, 1547  
   free interferon- $\alpha/\beta$  receptors in circulation in, 2730  
 Adolescents. *See also* Children  
   neuroblastoma in, 349  
 Adrenal suppression, megestrol acetate-related, in children, 397  
 African Americans. *See also* Race/ethnicity  
   brain tumor survival in, 603  
   breast cancer survival in, 894, 908  
   psychosocial factors in, 1299  
   endometrial cancer outcome in, vs. in whites, 176  
   mammographic breast density in, 590  
   in oncology, ways to increase, 2736 (letter)  
   XRCC3 polymorphism in, lung cancer risk and, 1701  
 Agnogenic myeloid metaplasia, interferon for, 100  
 AJCC Cancer Staging Manual, classification of isolated tumor cells in, 2741  
 Alaska Natives. *See also* Race/ethnicity  
   cancer rates among, 1262  
 Alemtuzumab  
   for chronic lymphocytic leukemia, 2657  
   for chronic lymphoproliferative disorders, 773  
 Alpha-fetoprotein, in germ cell tumors, salvage surgery and, 1635  
 Alternative medicine, clinical oncologists' attitudes toward, in Japan, 2302 (letter)  
 American Indians. *See also* Race/ethnicity  
   cancer rates among, 1262  
 American Joint Committee on Cancer Staging Manual, classification of isolated tumor cells in, 2741  
 Amphotericin B, with caspofungin, for invasive aspergillosis, 292  
 Anastrozole, for breast cancer  
   vs. fulvestrant, 229  
   with/without tamoxifen vs. tamoxifen alone, 1802  
 Androgen receptors, in breast cancer, 703  
 Anemia  
   aplastic  
     infections in, 86  
     sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor in, 2410  
   fatigue and, 1786  
 Angiogenesis. *See also* Vascular endothelial growth factor  
   in breast cancer, endocrine therapy efficacy and, 2125  
   inhibition of in breast cancer, trastuzumab and paclitaxel for, 1377  
 Angiogenic factors, circulating, monitoring of, in dendritic cell-based immunotherapy, 2291  
 Angiosarcoma  
   antiangiogenic therapy for, with pioglitazone, rofecoxib, and trofosfamide, 2251  
   of scalp, 1716  
 Antiangiogenic therapy, for angiosarcoma, with pioglitazone, rofecoxib, and trofosfamide, 2251  
 Antibiotics, for febrile neutropenia requiring hospitalization, 1039  
 Anticoagulation, prophylactic, in central nervous system lymphoma, 1239  
 Antiemesis, prophylactic palonosetron for, 2473  
 Antihypertensives, breast cancer and, 1334 (editorial), 1504  
 Antiretroviral therapy, Kaposi sarcoma and, 2440  
 Anxiety, in stem cell transplantation, music therapy for, 2723  
 Aplastic anemia  
   infections in, 86  
   sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor in, 2410  
 Apo2L, in hematologic disorders, 458  
 Ara-C. *See* Cytosine arabinoside  
 Arm  
   complications in, from axillary/sentinel node biopsy, in breast cancer, 690  
   lymphedema of  
     laser therapy for, 1114  
     in long-term breast cancer survivors, 679  
 Aromatase inhibitors, adjuvant, 1779 (editorial)  
 Asp835 mutations, in *FLT3* gene, in acute promyelocytic leukemia, 1206  
 L-Asparaginase, PEG, for multiple myeloma, 94  
 Aspergillosis, caspofungin with liposomal amphotericin B for, 292  
 Astrocytoma  
   of spinal cord, 554  
   tenascin-C in, prognosis and, 2430

ATAC clinical trial, 1802

Autologous stem cell transplantation. *See* Stem cell transplantation

## B

Barrett esophagus

hiatal hernia and, 940

reflux and, 940

Basal cell carcinoma, superficial radiotherapy for, 2708

Basement membrane, loss of, in ovarian cancer, 2607

B-cell lymphoma. *See* Lymphoma

Bcl-2

in basal cell carcinoma, prognosis and, 2708

in breast cancer, in primary tumor and metastatic nodes, prognosis and, 2554

in nonsmall cell lung cancer, prognosis and, 135

Behavioral therapy, in melanoma, 854

Benign prostatic hyperplasia, prostate cancer risk and, 1727

$\beta_2$  microglobulin, in mantle cell lymphoma, prognosis and, 2630

Bikunin gene expression, in ovarian cancer, prognosis and, 424

Biliary tract cancer, *H. pylori* infection and, 656 (letter)

Biopsy

core needle, in prostate cancer, as predictor of PSA recurrence in, 2344

lymph node

in breast cancer, short-term morbidity of upper limb after, 690

in ductal carcinoma in situ, 2083 (editorial)

Biphosphonates, for osteolytic bone metastases, 1318

Bladder cancer. *See also* Transitional cell carcinoma

cathepsin B in, 262

CD9 in, prognosis and, 1649

with extravesical extension, postoperative natural history of, 955

fibroblast growth factor receptor 3 mutations in, 737

gemcitabine and docetaxel for, 1863

genetic alterations in laser-capture-microdissected stroma adjacent to, 1830

heat shock proteins in, 970

motility-related protein-1 in, prognosis and, 1649

after primary transitional cell carcinoma of upper urinary tract, 1620

urokinase-type plasminogen activator in, 1995 (letter)

Bladder toxicity, of brachytherapy, in prostate cancer, 949

Blast crisis, in chronic myelogenous leukemia, sudden onset of, 81

Bleeding, rectal, after brachytherapy for prostate cancer, 949

Bleomycin, for Hodgkin disease, 978

with radiotherapy, 2393

Body mass index. *See* Obesity

Bombesin, cytotoxic analogues of, for gastric cancer, 1401

Bone marrow failure, sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor in, 2410

Bone marrow transplantation. *See also* Stem cell transplantation for breast cancer, candidemia and, 25

music therapy in, 2723

Bone metastasis

biphosphonates and radiotherapy for, 1318

in breast cancer, zoledronic acid vs. pamidronate disodium for, 1735

in multiple myeloma, zoledronic acid vs. pamidronate disodium for, 1735

osteolytic, biphosphonates and radiotherapy for, 1318

in renal cell carcinoma, zoledronic acid for, 962

Book reviews

*Cancer Medicine* 6 (Kufe et al.), 2511

*Cognitive Behavior Therapy for People with Cancer* (Moorey & Greer), 212

*Head and Neck Cancer: Emerging Perspectives* (Ensley, Gutkind, Jacobs, & Lippman), 1100

*Hormones, Genes, and Cancer* (Henderson, Ponder & Ross), 2511

*Mesothelioma* (Robinson & Chahinian), 213

Brachytherapy. *See also* Radiation therapy

for prostate cancer

late genitourinary/gastrointestinal toxicity and, 949

Patterns of Care study of, 1987

Brain metastasis

in esophageal cancer, 1925

in neuroblastoma, 155

in prostate cancer, 363

in thyroid cancer, 356

Brain tumors

desmoplastic medulloblastoma, in nevoid basal cell carcinoma syndrome, 618

glioblastoma

long-term survival in, 1745

salvage therapy for, 2678

tenascin-C in, prognosis and, 2430

glioma, low-grade pediatric, outcome in, 1243

medulloblastoma, dietetic intervention in, 1014

multiple primaries and, 562

nongerminomatous malignant germ cell, 369

oligodendrogliomas, COX-2 in, prognosis and, 1465

supratentorial primitive neuroectodermal, dietetic intervention in, 1014

survival in, racial differences in, 603

tenascin-C in, prognosis and, 2430

BRCA1 mutations

in breast cancer, 1327 (letter)

lymph node metastasis and tumor size correlation and, 1569

in non-Jewish Spanish-Americans, 597

Breast

magnetic resonance imaging of, frequency of "probably benign" interpretations in, 377

mammographic density of, racial differences in, 590

Breast cancer

adjuvant chemotherapy for

in older women, 1141

risk-benefit analysis for, 1150

anastrozole with/without tamoxifen vs. tamoxifen alone for, 1802

androgen receptors in, 703

antihypertensives and, 1334 (editorial), 1504

Bcl-2 in, in primary tumor and metastatic nodes, prognosis and, 2554

biology of, 1327 (letter)

bone marrow transplantation for, candidemia and, 25

bone metastases in, zoledronic acid vs. pamidronate disodium for, 1735

BRCA1 mutations in, 1327 (letter)

lymph node metastasis and tumor size correlation and, 1569

in non-Jewish Spanish-Americans, 597

breast-conserving therapy for

eligibility for, routine mammography and, 918

vs. mastectomy, for early-stage disease, 697

- positive margins and ipsilateral recurrence in, prognosis and, 2512 (letter)
- regional recurrence after, prognosis and, 2144, 2145
- routine mammography and, 918
- candidemia in, 25
- coagulopathy in, 1578
- docetaxel and pegylated liposomal doxorubicin for, 610
- ductal carcinoma in situ
- androgen receptors in, 703
  - occult micrometastasis in, 2083 (editorial), 2105
  - risk of, exercise and, 2161
- ductal lavage in, diagnostic sensitivity of, 2170
- early-onset, immunohistochemical biomarkers and HER-2/*neu* gene amplification in, in Korean v. white woman, 1587
- early-stage
- long-term outcome of, 679
  - mastectomy vs. breast conservation therapy for, 697
- in elderly, adjuvant chemotherapy for, 1141
- elderly survivors of, favorable cardiac risk in, 2
- exatecan mesylate for, 900
- filgastrim prophylaxis in, risk model for, 222
- fulvestrant vs. anastrozole for, 229
- HER-2/*neu* in, utility of testing for, 2547
- histologic grade of, racial differences in, 908
- hormone replacement therapy and, 1552 (letter)
- withdrawal of, short-term biologic response to, 2539
- intraductal, in younger vs. older women, 1102 (letter)
- isolated supraclavicular recurrence in, 11
- low fat/high-fiber diet in prevention of, 1782 (editorial), 1870
- lymph node biopsy in
- in ductal carcinoma in situ, 2083 (editorial)
  - short-term morbidity of upper limb after, 690
- lymph node metastasis in
- Bcl-2 and p53 in, prognosis and, 2554
  - in nonsentinel nodes, 2307
- mastectomy for
- vs. breast conservation therapy, for early stage cancer, 697
  - ductal lavage in, diagnostic sensitivity of, 2170
  - lymphedema after, laser therapy for, 1114
  - preoperative MRI in, 468
  - prophylactic, reoperation after, 2152
  - skin-sparing, 2316
- method of detection of, in initial vs. recurrent disease, 1596
- NCOA3 in, prognosis and, 18
- nutritional strategies for prevention of, 1782 (editorial), 1870
- p21<sup>Cip1</sup> up-regulation and p34<sup>Cdc2</sup> hyperphosphorylation in, chemosensitivity and, 1123
- p53 in, in primary tumor and metastatic nodes, prognosis and, 2554
- in pregnancy, 1055
- pregnancy after, survival and, 1131
- preoperative MRI in, 468
- preoperative radiofrequency ablation of, 1369
- after "probably benign" interpretations on MRI, 377
- prognosis in, psychosocial factors in, racial differences in, 1299
- radiotherapy for
- with isolated supraclavicular recurrence, 11
  - lung cancer after, 1331 (editorial), 1362, 1457
  - vs. mastectomy, in early stage disease, 697
  - routine mammography and, 918
  - thyroid cancer after, 1309
  - utilization rate for, 1977
- regional recurrence in, prognosis and, 2144
- screening for
- breast density on, racial differences in, 590
  - in initial vs. recurrent disease, 1596
  - in older women, primary physicians' role in, 1811
  - primary physicians' role in, 1811
  - routine, disease stage and eligibility for conservative treatment and, 918
  - tumor size and death rate and, 2114
- sentinel/axillary lymph node biopsy in, short-term morbidity of upper limb after, 690
- sentinel nodes in, intraoperative immunofluorescent evaluation of, 1562
- Size+Node method of predicting outcome in, 2133
- in smokers, lung cancer after, 1457
- stage at presentation of, routine mammography and, 918
- survival in
- psychosocial factors in, 1299
  - racial disparities in, 894, 908
  - syndecan-1 in, prognosis and, 474
  - TFAP2C in, prognosis and, 18
  - TOP1 in, prognosis and, 18
  - trastuzumab and paclitaxel for, for angiogenesis inhibition, 1377
  - tumor size and lymph node status in, prognosis and, 2133
  - vascular endothelial growth factor in, therapeutic efficacy and, 2125
  - Vinorelbine palliation for, 1325 (letter)
- Breast conservation therapy
- eligibility for, routine mammography and, 918
  - vs. mastectomy, for early stage disease, 697
  - positive margins and ipsilateral recurrence in, prognosis and, 2512 (letter)
  - regional recurrence after, prognosis and, 2145
  - for routine mammography and, 918
- Breast implants, after prophylactic mastectomy, reoperation for, 2152
- Breslow depth, melanoma signs and symptoms and, 344
- Bromodeoxyuridine, with radiotherapy, for central nervous system lymphoma, 1021
- Burkitt lymphoma, HIV-related, chemotherapy for, 1196
- C**
- c-ABL, in ovarian cancer, 758
- Calpain 6, in leiomyosarcoma, 1029
- Canalicular stenosis, docetaxel and, 504
- Cancer, incidence/prevalence of, among American Indians and Alaska Natives, 1262
- Capecitabine, for nonsmall cell lung cancer, with docetaxel, 1918
- Carboplatin
- for nonsmall cell lung cancer
  - vs. MIC/MVP, 542
  - in patients >70 years, 779
  - for prostate cancer, 269, 1842
  - with immunotherapy, 2592
- Cardiac disease, reduced risk for, in elderly breast cancer survivors, 2
- Cardiac transplantation, esophageal cancer after, mediastinal irradiation for, 2738
- Career development, in gynecologic cancer, 2075
- Caspofungin, with liposomal amphotericin B, for invasive aspergillosis, 292
- Catechol-O-methyltransferase, genetic polymorphisms of, in familial prostate cancer, 1411

- Cathepsin B, in bladder cancer, 262
- CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells, in gastrointestinal cancer, 1089
- CD9, in bladder cancer, prognosis and, 1649
- CD30/CD30L, in hematologic disorders, 458
- CD33, in acute myeloid leukemia, 2095
- CD40/CD40L, in hematologic disorders, 458
- CD86, in acute myeloid leukemia and myelodysplastic syndrome, 1681
- CDKN2A, in familial atypical multiple-mode melanoma-pancreatic carcinoma syndrome, 798
- Cefepime, for febrile neutropenia requiring hospitalization, 1039
- Central nervous system lymphoma  
bromodeoxyuridine with radiation therapy for, 1021  
thromboembolism in, 1239
- Central nervous system metastases, in neuroblastoma, 155
- Cerebral metastasis  
in esophageal cancer, 1925  
in neuroblastoma, 155  
in prostate cancer, 363  
in thyroid cancer, 356
- Cervical cancer  
behavioral factors in, 2009  
biology of, 2064  
chemoprevention of, 2044  
cyclin-dependent kinase inhibitors in, 1880  
decision science and, 2003  
diagnosis of, behavioral factors in, 2009  
fertility-sparing surgery for, 2052  
human papillomavirus and, 2064  
hysterectomy for, 2052  
imaging in, 2028  
computed tomography in, 2039  
optical technology in, 2009  
international conference on, 2001  
invasive, treatment innovations for, 2052  
locally advanced, concurrent radiotherapy, chemotherapy, and hyperthermia for, 277  
*matriptase/MT-SP1* in, prognosis and, 1898  
nursing role in prevention and treatment of, 2070  
obesity and, 814  
pelvic exenteration for, 2052  
quality of life and, behavioral factors in, 2009  
radiation therapy for, 2052  
screening for  
behavioral factors in, 2009  
nurse's role in, 2009  
sentinel node dissection in, 2514 (letter)  
sexual rehabilitation in, 2009  
surrogate endpoint biomarkers for, 2044  
TADG-15 in, prognosis and, 1898  
telomerase in, 2064  
vaccines for, 2044, 2064  
venous thrombosis in, 1514
- Cervical fluorophores, in cervical cancer, 2015
- Cervix, imaging of, 2028  
computed tomography in, 2039  
optical technology in, 2009
- Chemoradiation  
anemia in, erythropoietin- $\alpha$  for, 1072  
for central nervous system lymphoma, 1021  
for cervical cancer, 2052  
venous thrombosis and, 1514  
for esophageal cancer, with locoregional spread, 2177  
for Hodgkin disease, 2393  
for nonsinonasal neuroendocrine head and neck cancer, 2322
- Chemotherapy  
for acute lymphoblastic leukemia, in adult, 1337  
anemia in  
erythropoietin- $\alpha$  for, 1072  
fatigue and, 198, 1786  
for breast cancer, 229, 900  
adjuvant chemotherapy for, 1150  
candidemia and, 25  
in older women, 1141  
responsiveness to, *erbB2* overexpression and, 1123  
vascular endothelial growth factor and, 2125  
for Burkitt lymphoma, in HIV infection, 1196  
for cervical cancer, with concurrent radiotherapy and hyperthermia, 277  
for choroid metastasis, 1232  
for chronic myelogenous leukemia, 888  
clinical trials for. *See* Clinical trials  
for colorectal cancer, toxicity of, body mass index and, 484  
for cutaneous T-cell lymphoma, 993  
for diffuse large B-cell lymphoma, in elderly, 2651  
drug approval for, ethical issues in, 215 (editorial)  
endocrine therapy efficacy and, 2125  
for Ewing sarcoma, long-term complications of, 2687  
for extraocular retinoblastoma, 1292  
for extremity soft tissue sarcoma, 1483  
for gastric cancer, histologic tumor regression grade in, 1521  
for gastrointestinal stromal tumors, 2693  
for glioblastoma, salvage therapy for, 2678  
for hepatic metastases in colorectal cancer, 320  
for hepatoblastoma, 668  
for Hodgkin disease, 978  
for low-grade gliomas, in children, 1243  
for lung cancer, clinical trials for, cost-effectiveness of, 1491  
for lymphoma, 983  
for melanoma, 1355  
mucositis in, 1531  
nausea and vomiting in  
assessment tool for, 645  
palonosetron prophylaxis for, 2473  
for neuroblastoma, 2488  
for nongerminomatous intracranial malignant germ cell tumors, 369  
for non-Hodgkin lymphoma, febrile neutropenia in, hospitalization for, 2402  
for nonsmall cell lung cancer, 542, 1707, 1918  
in patients >70 years, 779  
for osteosarcoma, 832, 2447  
of head and neck, 1670  
response to, P-glycoprotein and, 581  
sensitivity to, reduced folate carrier protein and, 1947  
for ovarian cancer, 1664  
for prostate cancer, 269, 1603, 1627, 1842, 1855, 2088 (editorial), 2192  
with immunotherapy, 2592  
in metronomic therapy, 1643  
with radiotherapy. *See* Chemoradiation  
for renal cell carcinoma, 61, 1837  
for rhabdomyosarcoma, in adults, 571  
for soft tissue sarcoma, 2693  
for thymic cancer, 926
- Children. *See also specific pediatric cancers*  
diffuse lymphoblastic lymphoma in, outcome in, 1283

- low-grade gliomas in, outcome in, 1243  
 megestrol acetate for, adrenal suppression and, 397
- Cholangiocarcinoma**  
 hilar, patterns of initial recurrence in, 1689  
 serum MUC5AC mucin in, prognosis and, 1438
- Chordomas, skull base/non-skull base, nuclear pleomorphism in, prognosis and, 1934**
- Choroid metastasis, clinical features and treatment of, 1232**
- Chromate workers, respiratory tract chromium accumulation in, 2420**
- Chromogranin A, serial measurement of, for gastrinomas, 249**
- Chronic hepatitis, estrogen receptor- $\beta$  in, clinicopathologic correlates of, 529**
- Chronic leukemia. *See* Leukemia**
- Chronic lymphoproliferative disorders, alemtuzumab for, 773**
- Chronic myeloproliferative disorders, interferon for, 100**
- Chronotherapy, 861 (letter)**
- Cigarette smoking**  
 in cancer patients, cessation strategies for, 632  
 lung cancer in breast cancer survivors and, 1457  
 after lung cancer screening, 2495  
 oropharyngeal cancer and, *UGT1A10* polymorphisms and, 872
- Cirrhosis, estrogen receptor- $\beta$  in, clinicopathologic correlates of, 529**
- Cisplatin**  
 for advanced seminoma, 745  
 for esophageal cancer, with radiotherapy, 2177  
 for extraocular retinoblastoma, 1292  
 for nonsmall cell lung cancer, 128, 1707  
   vs. gemcitabine-carboplatin, 542  
 for paranasal sinus cancer, 2214  
 for thymic cancer, 926
- c-KIT, in ovarian cancer, 758**
- Clear cell ependymoma, 2232**
- Clinical trials**  
 ATAC, 1802  
 cost-effectiveness of, 1491  
 disclosure of "new findings" to candidates for, 885  
 ethical issues in, 215 (editorial)  
 expectations of benefit from, 166  
 for lung cancer, cost-effectiveness of, 1491  
 for renal cell carcinoma, response assessment classification in, 1611
- c-Met expression, in tall cell variant papillary thyroid cancer, 1386**
- C-myc, in medulloblastoma, 841**
- Coagulopathy, in breast cancer, 1578**
- Cognitive-behavioral interventions, in melanoma, 854**
- Colon cancer. *See* Colorectal cancer**
- Colonic epithelial tumors, translation initiation factor eIF-2 $\alpha$  in, 1080**
- Colorectal cancer**  
 care prevalence of, in United States, 1253  
 CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in, 1089  
 female long-term survivors of, quality of life and social networks of, 1749  
 hepatic metastasis in, hepatic cryotherapy and regional chemotherapy for, 320  
 hereditary nonpolyposis, endometrial cancer surveillance in women at risk for, 1772 (letter)  
*hMLH1* in, high-resolution methylation analysis of, 1540  
 reirradiation and hyperthermia for, 1759  
 synchronous, microsatellite instability in, 48  
 translation initiation factor eIF-2 $\alpha$ , 1080  
 treatment-related toxicity in, body mass index and, 484
- Complementary and alternative medicine, clinical oncologists' attitudes toward, in Japan, 2302 (letter)**
- Computed tomography**  
 in cervical cancer, 2039  
 in lung cancer screening, smoking abstinence after, 2495
- Conjunctival MALT lymphoma, radiotherapy for, 865**
- Core needle biopsy, in prostate cancer, as predictor of PSA recurrence in, 2344**
- Coronary heart disease, reduced risk for, in elderly breast cancer survivors, 2**
- Correspondence, 430, 872, 1101, 1325, 1552, 1772, 1995, 2302, 2512, 2736**
- Corticosteroids. *See also* Prednisone**  
 with megestrol acetate, in children, 397
- Cortisol, megestrol acetate-related decrease in, in children, 397**
- Cost analysis, for cervical cancer, 2003**
- COX-2**  
 in oligodendrogliomas, prognosis and, 1465  
 in ovarian cancer, 2607  
 tumor vascularity and, 1423
- COX-2 inhibitors, in hepatocellular carcinoma prevention, 661**
- Craniofacial surgery, for skull base tumors, 1179**
- Cryotherapy, for hepatic metastases, in colorectal cancer, 320**
- Cutaneous angiosarcoma, of scalp, 1716**
- Cutaneous T-cell lymphoma**  
 juvenile-onset mycosis fungoides, outcome in, 2282  
 pegylated liposomal doxorubicin for, 993
- Cyclin D1, in early-onset breast cancer, in Korean v. white woman, 1587**
- Cyclin-dependent kinase inhibitors**  
 in cervical cancer, prognosis and, 1880  
 in leiomyosarcoma, 1029
- Cyclooxygenase-2**  
 in oligodendrogliomas, prognosis and, 1465  
 in ovarian cancer, 2607  
 tumor vascularity and, 1423
- Cyclooxygenase-2 inhibitors, in hepatocellular carcinoma prevention, 661**
- Cyclophosphamide**  
 for breast cancer, responsiveness to, *erbB2* overexpression and, 1123  
 for Burkitt lymphoma, in HIV infection, 1196  
 for extraocular retinoblastoma, 1292  
 for non-Hodgkin lymphoma, hospitalization for febrile neutropenia and, 2402  
 for prostate cancer, 1603  
 in metronomic therapy, 1643
- CYP19, genetic polymorphisms of, in familial prostate cancer, 1411**
- Cytosine arabinoside**  
 for Burkitt lymphoma, in HIV infection, 1196  
 for chronic myelogenous leukemia, 888  
 for lymphoma, 983

## D

- Dab-2, in ovarian cancer, 2607**
- Darbepotin- $\alpha$ , for fatigue, 1786**
- DARPP-32, in adenocarcinoma, 1547**
- Decision science, cervical cancer and, 2003**
- Decitabine, for chronic myelogenous leukemia, 522**
- Deep vein thrombosis**  
 in breast cancer, 1578



- in central nervous system lymphoma, 1239
  - in cervical cancer, 1514
  - Dendritic cell-based immunotherapy, monitoring of circulating angiogenic factors in, 2291
  - Denmark, prognostic implications of HER-2 overexpression in ovarian cancer in, 66
  - Depigmentation, of skin, imatinib mesylate-induced, 2483
  - Depression
    - fatigue and, 198
    - in stem cell transplantation, music therapy for, 2723
  - Des-gamma-carboxy prothrombin index, in hepatocellular carcinoma, prognosis and, 2671
  - Desmoplastic medulloblastoma, in nevoid basal cell carcinoma syndrome, 618
  - Dexamethasone, for prostate cancer, in metronomic therapy, 1643
  - Diaphanous 3, in leiomyosarcoma, 1029
  - Diet. *See also* Nutritional support
    - low-fat/high-fiber, in breast cancer prevention, 1782 (editorial), 1870
    - rectal mucosal cell proliferation and, 1161
  - Diethylstilbestrol, for prostate cancer, 1603
  - Diffuse large B-cell lymphoma
    - doxorubicin-based chemotherapy for, in elderly, 2651
    - prognosis of, in younger patients, 516
  - Diffuse lymphoblastic lymphoma, pediatric, outcome in, 1283
  - Disabled-2, in ovarian cancer, 2607
  - DNA mismatch repair defects, 2091 (editorial), 2199
  - Docetaxel
    - for advanced cancer, with pegylated liposomal doxorubicin, 610
    - nasolacrimal duct obstruction and, 504
    - for non-small cell lung cancer, with capecitabine, 1918
    - for prostate cancer, 1627, 1855
    - with immunotherapy, 2592
  - Dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein, in adenocarcinoma, 1547
  - Doublecortin, in leiomyosarcoma, 1029
  - Doxorubicin
    - for Burkitt lymphoma, in HIV infection, 1196
    - for diffuse large B-cell lymphoma, in elderly, 2651
    - for extraocular retinoblastoma, 1292
    - for Hodgkin disease, 978
    - for neuroblastoma, 2488
    - for non-Hodgkin lymphoma, hospitalization for febrile neutropenia and, 2402
    - pegylated liposomal
      - for cutaneous T-cell lymphoma, 993
      - with docetaxel, for advanced cancer, 610
    - for thymic cancer, 926
  - Drug approval. *See also* Clinical trials
    - ethical issues in, 215 (editorial)
  - Ductal carcinoma in situ
    - androgen receptors in, 703
    - occult micrometastasis in, 2083 (editorial), 2105
    - risk of, exercise and, 2161
  - Ductal lavage, in breast cancer, diagnostic sensitivity of, 2170
  - DX-8951f, for breast cancer, 900
- E**
- Echinococcal infection, in cancer prevention, 1998 (letter)
  - Ecteinascidin 743, for recurrent osteosarcoma, 832
  - Editorials, 1, 215, 219, 1779, 1782, 2083, 2088, 2091
  - Educational level, survival and, 1497
  - eIF-2 $\alpha$ , in melanocytic and colonic epithelial tumors, 1080
  - Elderly
    - breast cancer in
      - adjuvant chemotherapy for, 1141
      - screening for, primary care physicians' role in, 1811
    - breast cancer survivors, favorable cardiac risk in, 2
    - chronic myelogenous leukemia in, imatinib mesylate for, prognosis and, 1105
    - diffuse large B-cell lymphoma in, doxorubicin-based chemotherapy for, 2651
    - endometrial cancer in, aggressiveness of, 2368
    - mammography in, primary physicians' role in, 1811
    - non-Hodgkin lymphoma in, 1188
    - non-small cell lung cancer in, carboplatin-paclitaxel for, 779
  - Emesis, chemotherapy-induced
    - assessment tool for, 645
    - palonosetron prophylaxis for, 2473
  - Emotional distress. *See also* Quality of life
    - in autologous stem cell transplantation, music therapy for, 2723
    - in melanoma, cognitive-behavioral interventions for, 854
  - Endocrine cancers, poorly differentiated, genetic alterations in, 1273
  - Endocrine therapy
    - for breast cancer, vascular endothelial growth factor and, 2125
    - for prostate cancer, number-needed-to-treat analysis of, 2351
  - End of life care, palliative care in, oncologists' attitudes toward, 2502
  - Endometrial cancer
    - in elderly, aggressiveness of, 2368
    - hMLH1* in, high-resolution methylation analysis of, 1540
    - outcome in, racial differences in, 176
    - steroid receptor coactivators and corepressors in, 2207
    - surveillance for, in women at risk for hereditary nonpolyposis colorectal cancer, 1772 (letter)
  - Endometrial hyperplasia, steroid receptor coactivators and corepressors in, 2207
  - Endometrial polyps, tamoxifen-related, *K-ras* mutations in, 1890
  - Endometrial thickening, secondary ultrasonographic, after tamoxifen, 431 (letter)
  - Endometriosis, ovarian cancer and, 1658
  - Endoscopic management, of transitional cell carcinoma of upper urinary tract, 55
  - Endostatin, in hepatocellular carcinoma, tumor vascularity and, 1101 (letter)
  - Enteral nutrition. *See* Nutritional support
  - Ependymoma, clear cell, 2232
  - Epidermal growth factor, neuropilin-1 and, in pancreatic cancer, 720
  - Epiphora, docetaxel and, 504
  - Epoetin- $\alpha$ , for anemic patients receiving chemoradiation, 1072
  - Epstein-Barr virus DNA, in nasopharyngeal cancer, prognosis and, 288
  - Epstein-Barr virus latent membrane protein 1 gene, in mucosal recurrent nasopharyngeal carcinoma, 2385
  - erbB2*, in breast cancer, chemosensitivity and, 1123
  - Errata, 659, 1104, 2000, 2743
  - Erythropoietin
    - for cervical cancer, venous thrombosis and, 1514
    - for fatigue, 1786
  - Esophageal cancer
    - body size and, 940
    - CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in, 1089
    - cerebral metastasis in, 1925

- chemoradiation for, 2177  
 hiatal hernia and, 940  
 mediastinal irradiation for, after heart transplant, 2738 (letter)  
 reflux and, 940  
 sentinel node mapping in, 932
- Esophagus, Barrett  
 hiatal hernia and, 940  
 reflux and, 940
- Essential thrombocythemia, interferon for, 100
- Estradiol, dietary fat/fiber and, 1870
- Estramustine  
 for prostate cancer, 269, 1842, 2192  
 with immunotherapy, 2592  
 for renal cell cancer, 1837
- Estrogen, cardioprotective effects of, in elderly breast cancer survivors, 2
- Estrogen receptor(s)  
 $\alpha$ -type, genetic polymorphisms of, in familial prostate cancer, 1411  
 $\beta$ -type, in liver cancer, clinicopathologic correlates of, 529  
 in breast cancer, after withdrawal of hormone replacement therapy, 2539  
 in early-onset breast cancer, in Korean v. white woman, 1587  
 endometriosis-associated ovarian cancer and, 1658
- Estrogen receptor antagonists, for breast cancer, 229
- Estrogen replacement therapy  
 breast cancer and, 1552 (letter)  
 withdrawal of in breast cancer, short-term biologic response to, 2539
- Ethical issues, 1555  
 in drug approval, 215 (editorial)
- Etoposide  
 for Burkitt lymphoma, in HIV infection, 1196  
 for extraocular retinoblastoma, 1292  
 for prostate cancer, 269, 2192  
 for thymic cancer, 926
- Ewing sarcoma, long-term survivors of, complications in, 2687
- Exatecan mesylate, for breast cancer, 900
- Exercise  
 ductal carcinoma in situ risk and, 2161  
 for fatigue, 1786
- Extraadrenal pheochromocytoma, high-dose  $^{131}$ I-metaiodobenzylguanidine for, 239
- Extremity, upper  
 complications in, from axillary/sentinel node biopsy, in breast cancer, 690  
 lymphedema of  
 laser therapy for, 1114  
 in long-term breast cancer survivors, 679
- Extremity sarcoma, pleomorphic, myoid differentiation in, prognosis and, 805
- F**
- Familial atypical multiple-mode melanoma-pancreatic carcinoma syndrome, phenotype in, 798
- Familial sarcoma, 1947
- Fat, dietary, breast cancer risk and, 1782 (editorial), 1870
- Fatigue  
 evaluation and treatment of, 1786  
 psychologic distress and, 198
- Febrile neutropenia, requiring hospitalization  
 in CHOP, CHOP-2, or CNOP chemotherapy, 2402  
 imipenem and cefepime for, 1039  
 in non-Hodgkin lymphoma, 2402
- FGFR3*, in urine sediment DNA, in bladder cancer, 737
- FHIT protein, in poorly differentiated endocrine carcinomas, 1273
- Fiber, dietary  
 breast cancer risk and, 1782 (editorial), 1870  
 rectal mucosal cell proliferation and, 1161
- Fibroblast growth factor receptor 3 mutations, in urine sediment DNA, in bladder cancer, 737
- Fibroblast growth factor receptor 4 single nucleotide polymorphism, in soft tissue sarcoma, prognosis and, 2245
- Field cancerization, in upper urinary tract, 1620
- Fifth phacomatosis, desmoplastic medulloblastoma in, 618
- Filgastrim, prophylactic, for breast cancer, risk model for, 222
- FLT3* gene, Asp835 mutations in, in acute promyelocytic leukemia, 1206
- $^{18}$ -Fluoro-2-deoxyglucose positron emission tomography  
 in nasopharyngeal cancer, 283  
 in recurrent oral squamous cell carcinoma, 2257
- Fluorophores, cervical, 2015
- 5-Fluorouracil, for breast cancer, responsiveness to, *erbB2* overexpression and, 1123
- FMS*-like tyrosine kinase 3 gene, Asp835 mutations in, in acute promyelocytic leukemia, 1206
- Fractures, pathologic, in long-term Ewing sarcoma survivors, 2687
- Fulvestrant, vs. anastrozole, for breast cancer, 229
- Fungal infections, in aplastic anemia, 86
- Fusarium* infection, in hematologic malignancies, prognostic factors in, 315
- G**
- Gallbladder cancer, patterns of initial recurrence in, 1689
- Ganglioneuroblastoma, nodular, prognostic subsets in, 2274
- Gastric cancer  
 body mass index and, 940  
 CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in, 1089  
 chemotherapy for, histologic tumor regression grade in, 1521  
 hiatal hernia and, 940  
 reflux and, 940  
*REG* expression in, prognosis and, 1394  
 targeted cytotoxic somatostatin/bombesin analogues for, 1401  
 trefoil factor 1 transcript in, 2184
- Gastrin, serial measurement of, for gastrinomas, 249
- Gastrinomas  
 immunophenotype of, 1967  
 tumor burden changes in, serial chromogranin A and gastrin measurements for, 249
- Gastroesophageal reflux disease, esophageal/gastric cancer risk and, 940
- Gastrointestinal cancer  
 CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in, 1089  
 poorly differentiated endocrine, genetic alterations in, 1273
- Gastrointestinal stromal tumors, temozolomide for, 2693
- Gemcitabine  
 for Hodgkin disease, 978  
 for nonsmall cell lung cancer, 128, 1707  
 vs. MIC/MVP, 542  
 plus oxaliplatin, 2664  
 pulmonary toxicity of, 978
- Gemtuzumab ozogamicin, for acute myeloid leukemia, 2095
- Germ cell tumors  
 with elevated tumor markers, salvage surgery for, 1635  
 nongerminomatous intracranial, 369

Gleason score, in prostate cancer, prognosis and, 2560  
Glioblastoma  
long-term survival in, 1745  
salvage therapy for, 2678  
tenascin-C in, prognosis and, 2430  
Glioma, low-grade pediatric, outcome in, 1243  
Glottic cancer, radiotherapy for, 765  
Glucocorticoids. *See also* Prednisone  
with megestrol acetate, in children, 397  
Gorlin syndrome, desmoplastic medulloblastoma in, 618  
Grantsmanship, in gynecologic cancer, 2075  
Granulocyte-colony-stimulating factor  
with ifosfamide and mesna, for mesothelioma, 331  
for prostate cancer, with chemotherapy, 2592  
Granulocyte-macrophage-colony stimulating factor, interleukin 3 and, in bone marrow failure, 2410  
Gynecologic cancer investigator, career development of, 2075

# H

Head and neck cancer. *See also specific types*  
nonsinonasal neuroendocrine, management of, 2322  
outcome in, educational level and, 1497  
pathologic vs. clinical lymph node staging in, 508  
radiotherapy for, racial factors in outcome of, 2467  
recurrent, [<sup>18</sup>F]-2-fluorodeoxyglucose positron emission tomography in, 2257  
UGT1A10 polymorphisms in, 872  
Head and neck osteosarcoma, National Cancer Data Base report on, 1670  
Heart disease, reduced risk for, in elderly breast cancer survivors, 2  
Heart transplantation, esophageal cancer after, mediastinal irradiation for, 2738  
Heat shock proteins, in bladder cancer, 970  
*Helicobacter pylori* infection, benign and malignant biliary disease and, 656 (letter)  
Hemangioendothelioma, antiangiogenic therapy for, with pioglitazone, rofecoxib and trofosfamide, 2251  
Hematologic disorders, tumor necrosis factor superfamily in, 458  
Hematologic malignancies. *See also specific sites and types*  
aspergillosis in, caspofungin with liposomal amphotericin B for, 292  
*Fusarium* infection in, prognostic factors in, 315  
tumor necrosis factor superfamily in, 458  
Hepatic cryotherapy, for hepatic metastases, in colorectal cancer, 320  
Hepatic metastases  
in colorectal cancer, hepatic cryotherapy and regional chemotherapy for, 320  
percutaneous radiofrequency ablation of, 2303 (letter)  
Hepatic transplantation, for hepatoblastoma, 668  
Hepatitis, estrogen receptor- $\beta$  in, clinicopathologic correlates of, 529  
Hepatoblastoma, current status of research and treatment in, 668  
Hepatocellular carcinoma  
CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in, 1089  
des-gamma-carboxy prothrombin index in, prognosis and, 2671  
estrogen receptor- $\beta$  in, clinicopathologic correlates of, 529  
hepatoma-derived growth factor in, prognosis and, 1444  
osteopontin in, prognosis and, 119  
percutaneous radiofrequency ablation therapy for, 433 (letter)

prevention of, cyclooxygenase-2 inhibitors in, 661  
serum endostatin in, tumor vascularity and, 1101 (letter)  
telomere length in, prognosis and, 110  
Hepatoma-derived growth factor, in hepatocellular cancer, prognosis and, 1444  
HER-2/*neu*  
in breast cancer, utility of testing for, 2547  
in early-onset breast cancer, in Korean v. white woman, 1587  
in ovarian cancer, prognosis and, 66  
Hereditary nonpolyposis colorectal cancer, endometrial cancer surveillance in women at risk for, 1772 (letter)  
Hernia, hiatal, esophageal/gastric cancer risk and, 940  
HERV-E, in prostate cancer, 187  
Hiatal hernia, esophageal/gastric cancer risk and, 940  
Highly active antiretroviral therapy, Kaposi sarcoma and, 2440  
Hilar cholangiocarcinoma, patterns of initial recurrence in, 1689  
Hippocratic tradition, 1555  
Hispanics. *See also* Race/ethnicity  
BRCA1 mutations in, 597  
mammographic breast density in, 590  
XRCC3 polymorphism in, lung cancer risk and, 1701  
HIV infection. *See* Human immunodeficiency virus infection  
*hMLH1*, high-resolution methylation analysis of, in endometrial and colorectal cancer, 1540  
*hMLH1* promoter regulation, in ovarian cancer, 2199  
Hodgkin disease. *See also* Hematologic malignancies; Lymphoma  
ABVG regimen for, 978  
chemoradiation for, 2393  
HIV-related, population-based patterns of, 300  
recurrent, rituximab for, 310  
Homoharringtonine, for chronic myelogenous leukemia, 888  
Hormonal therapy  
for breast cancer, vascular endothelial growth factor and, 2125  
for prostate cancer, number-needed-to-treat analysis of, 2351  
Hormone receptors. *See* Estrogen receptor(s); Progesterone receptor(s)  
Hormone replacement therapy  
breast cancer and, 1552 (letter)  
withdrawal of in breast cancer, short-term biologic response to, 2539  
Hormones, sex, dietary fat/fiber and, 1870  
Human chorionic gonadotropin, in germ cell tumors, salvage surgery and, 1635  
Human endogenous retrovirus E envelope genes, in prostate cancer, 187  
Human immunodeficiency virus infection  
Burkitt lymphoma in, chemotherapy for, 1196  
Hodgkin disease in, population-based patterns of, 300  
Kaposi sarcoma in, highly active antiretroviral therapy and, 2440  
Human papillomavirus, cervical cancer and, 2064  
Human telomerase reverse transcriptase  
in hepatocellular cancer, prognosis and, 110  
in nonsmall cell lung cancer, prognosis and, 1008  
Hydatid disease, in cancer prevention, 1998 (letter)  
Hydrocortisone, with megestrol acetate, in children, 397  
Hypercoagulability, in breast cancer, 1578  
Hyperthermia, 219 (editorial)  
for cervical cancer, with concurrent radiotherapy and chemotherapy, 277  
for rectal cancer, 1759  
Hyperuricemia, rasburicase for, 1048  
Hypocortisolism, megestrol acetate-related, in children, 397



Hypodiploidy, in acute lymphoblastic leukemia, prognosis and, 2715

Hypopigmentation, of skin, imatinib mesylate-induced, 2483

Hysterectomy, for cervical cancer, 2052

## I

### Ifosfamide

for Burkitt lymphoma, in HIV infection, 1196

for extraocular retinoblastoma, 1292

with mesna and granulocyte-colony-stimulating factor, for mesothelioma, 331

for nonsmall cell lung cancer, vs. gemcitabine-carboplatin, 542

for paranasal sinus cancer, 2214

### Imatinib mesylate

for chronic myelogenous leukemia, 437, 888, 1776 (letter)

age-prognosis relationship and, 1105

in children, 2643

chromosomal abnormalities in Ph-negative metaphases and, 1905

after interferon- $\alpha$  therapy, 1430

vs. interferon- $\alpha$  therapy, 2636

skin hypopigmentation and, 2483

<sup>123I</sup>/131I-MIBG, for neuroblastoma, thyroid protection in, 389

Imipenem, for febrile neutropenia requiring hospitalization, 1039

### Immunization

for cervical cancer, 2044

with plasmid DNA vaccine, for melanoma, 144

Immunofluorescence, in intraoperative evaluation of sentinel nodes, in breast cancer, 1562

Immunohistochemical biomarkers, in early-onset breast cancer, in Korean v. white woman, 1587

Immunoradiometric assay, for thyroglobulin, vs. radioimmunoassay, 41

### Immunotherapy

dendritic cell-based, monitoring of circulating angiogenic factors in, 2291

for prostate cancer, with chemotherapy, 2592

for renal cell carcinoma, with nephrectomy, survival prediction for, 2566

Incidence, among American Indians and Alaska Natives, 1262

Incremental cost-effectiveness ratio, for lung cancer, 1491

Infection control, for hospitalized SARS patient, 2739

Infections, in aplastic anemia, 86

Interferon- $\alpha$ , for chronic myelogenous leukemia, 437, 888, 2636

Interferon, for chronic myeloproliferative disorders, 100

Interferon- $\alpha/\beta$  receptors, in adenocarcinoma, 2730

Interleukin-2, for renal cell carcinoma, with nephrectomy, survival prediction for, 2566

Interleukin-3, granulocyte-macrophage-colony stimulating factor and, in bone marrow failure, 2410

Interleukin-6, in Hodgkin disease, rituximab effects on, 310

Interleukin-17B, in leiomyosarcoma, 1029

International Conference on Cervical Cancer, 2001

International Neuroblastoma Pathology Classification, revision of, 2274

International Prognostic Index, for diffuse large B-cell lymphoma, in younger patients, 516

3-Iodobenzylguanidine, for neuroblastoma, thyroid protection in, 389

Irinotecan, for renal cell carcinoma, 61

Isolated tumor cells, TNM classification of, 2741

## J

Japan, clinical oncologists' attitudes toward complementary and alternative medicine in, 2302 (letter)

## K

Kaposi sarcoma, AIDS-related, highly active antiretroviral therapy and, 2440

Ketoconazole, for prostate cancer, 1855

### Ki-67

in breast cancer, after withdrawal of hormone replacement therapy, 2539

in endometrial hyperplasia/carcinoma, steroid receptor coactivators and corepressors and, 2207

Koreans, early-onset breast cancer in, immunohistochemical biomarkers and HER-2/*neu* gene amplification in, 1587

K-ras mutations, in tamoxifen-related endometrial polyps, 1890

## L

Lacrimal duct obstruction, docetaxel and, 504

Lacrimal glands, MALT lymphoma of, radiotherapy for, 865

Laser desorption/ionization time-of-flight spectrometry, in prostate cancer, for biomarker discovery, 2576

Laser therapy, for postmastectomy lymphedema, 1114

Latent membrane protein 1 gene, in mucosal recurrent nasopharyngeal carcinoma, 2385

Latinos/Latinas. *See also* Race/ethnicity

*BRCA1* mutations in, 597

mammographic breast density in, 590

*XRCC3* polymorphism in, lung cancer risk and, 1701

Legal issues, 1555

Leiomyosarcoma, differential gene expression in, 1029

Letters to editor, 430, 872, 1101, 1325, 1552, 1772, 1995, 2302, 2512, 2736

Leukemia. *See also* Hematologic malignancies

acute lymphoblastic

in adults, biology and treatment of, 1337

hypodiploidy in, prognosis and, 2715

soluble tumor necrosis factor in, prognosis and, 625

acute myeloid

gemtuzumab ozogamicin for, 2095

soluble CD86 in, prognosis and, 1681

acute promyelocytic, Asp835 mutations in *FLT3* gene in, 1206

chronic lymphocytic

alemtuzumab for, 773

for residual disease, 2657

pulmonary complications in, 1912

chronic myelogenous

biology of, 437

blast crisis in, sudden onset of, 81

decitabine for, 522

diagnosis of, 437

imatinib mesylate for, 437, 888, 1776 (letter)

age-prognosis relationship and, 1105

in children, 2643

chromosomal abnormalities in Ph-negative metaphases and, 1905

after interferon- $\alpha$ , 1430

vs. interferon- $\alpha$ , 2636

skin hypopigmentation and, 2483

interferon- $\alpha$  for

with cytarabine and homoharringtonine, 888

vs. imatinib mesylate, 2636

imatinib mesylate after, 1430

- laboratory findings in, 437
- prognosis of, 437
  - in elderly, 1105
- treatment of, 437, 1105
- prolymphocytic, alemtuzumab for, 773
- tumor necrosis factor in, 458
- Liposomal amphotericin B, with caspofungin, for invasive aspergillosis, 292
- Liver cancer. *See also* Hepatocellular carcinoma
  - estrogen receptor- $\beta$  in, clinicopathologic correlates of, 529
- Liver metastases
  - in colorectal cancer, hepatic cryotherapy and regional chemotherapy for, 320
  - percutaneous radiofrequency ablation of, 2303 (letter)
- Liver transplantation, for hepatoblastoma, 668
- LMP-1*, in mucosal recurrent nasopharyngeal carcinoma, 2385
- Loss of heterozygosity, in poorly differentiated endocrine carcinomas, 1273
- Low-fat diet, in breast cancer prevention, 1782 (editorial), 1870
- Lumpectomy
  - eligibility for, routine mammography and, 918
  - vs. mastectomy, for early stage cancer, 697
  - positive margins and ipsilateral recurrence in, prognosis and, 2512 (letter)
  - regional recurrence after, prognosis and, 2145
- Lung cancer
  - in breast cancer
    - after radiotherapy, 1331 (editorial), 1362, 1457
    - in smokers, 1457
  - in chromate workers, 2420
  - clinical trials for, cost-effectiveness of, 1491
  - CT screening for, smoking abstinence after, 2495
  - nonsmall cell
    - bcl-2* in, prognosis and, 135
    - carboplatin-paclitaxel for, in patients >70 years, 779
    - gemcitabine, paclitaxel, and cisplatin induction for, 1707
    - gemcitabine and cisplatin for, 128
    - gemcitabine-carboplatin vs. MIC/MVP for, 542
    - gemcitabine for, 337
    - human telomerase reverse transcriptase mRNA in, prognosis and, 1008
    - with tumor of 2 cm or less, management and prognosis of, 535
    - vascular endothelial growth factor-C in, nodal metastasis and, 1217
    - TSLC1* in, clinical/prognostic significance of, 1002
    - XRCC3* polymorphism and, in minority populations, 1701
- Lung disorders, in chronic lymphocytic leukemia, 1912
- Lymphedema
  - in long-term breast cancer survivors, 679
  - postmastectomy, laser therapy for, 1114
- Lymph node(s)
  - retroperitoneal, dissection of, for sex-cord stromal tumors, 753
- sentinel
  - biopsy of. *See* Lymph node biopsy
  - in breast cancer, intraoperative immunofluorescent evaluation of, 1562
  - dissection of, in cervical cancer, 2514 (letter)
  - mapping of, in esophageal cancer, 932
- Lymph node biopsy
  - axillary/sentinel node, in breast cancer, short-term morbidity of upper limb after, 690
  - sentinel node, in ductal carcinoma in situ, 2083 (editorial)

- Lymph node metastasis
  - in breast cancer
    - Bcl-2* and *p53* in, prognosis and, 2554
    - in nonsentinel nodes, 2307
    - tumor size and, 1569
  - mechanisms of, 413
  - in melanoma, vascular endothelial growth factor-C and, 789
  - in nonsmall cell lung cancer, vascular endothelial growth factor-C and, 1217
  - in papillary microcarcinoma of thyroid, 31
  - in thyroid cancer, 712
- Lymphoblastic lymphoma, pediatric, outcome in, 1283
- Lymphoma. *See also* Hematologic malignancies
  - Burkitt, HIV-related, chemotherapy for, 1196
  - central nervous system
    - bromodeoxyuridine with radiation therapy for, 1021
    - thromboembolism in, 1239
  - cutaneous T-cell
    - juvenile-onset mycosis fungoides, outcome in, 2282
    - pegylated liposomal doxorubicin for, 993
  - diffuse large B-cell
    - doxorubicin-based chemotherapy for, in elderly, 2651
    - prognosis of, in younger patients, 516
  - in elderly, 1188
  - febrile neutropenia in, hospitalization for, 2402
  - high-risk aggressive, chemotherapy and autografting for, 983
  - Hodgkin. *See* Hodgkin disease
  - large B-cell, prognosis of, in younger patients, 516
  - lymphoblastic, pediatric, outcome in, 1283
  - MALT, of ocular adnexa, radiotherapy for, 865
  - mantle cell
    - autologous stem cell transplant for, outcome of, 2630
    - $\beta_2$  microglobulin in, prognosis and, 2630
  - tumor necrosis factor in, 458

## M

- Magnetic resonance imaging
  - of breast
    - frequency of "probably benign" interpretations in, 377
    - preoperative, 468
    - for nasopharyngeal cancer, vs.  $^{18}$ -fluoro-2-deoxyglucose positron emission tomography, 283
  - Magnetic resonance imaging-guided brachytherapy, for prostate cancer, genitourinary/gastrointestinal toxicity of, 949
- Malignant hemangioendothelioma, antiangiogenic therapy for, with pioglitazone, rofecoxib and trofosamide, 2251
- Malignant melanoma. *See* Melanoma
- Malignant mesothelioma. *See* Mesothelioma
- Malignant pheochromocytoma, high-dose  $^{131}$ -metaiodobenzylguanidine for, 239
- Malignant pleural effusion, in chronic lymphocytic leukemia, 1912
- MALT lymphoma, of ocular adnexa, radiotherapy for, 865
- Mammography
  - breast density on, racial differences in, 590
  - in initial vs. recurrent disease, 1596
  - in older women, primary physicians' role in, 1811
  - primary physicians' role in, 1811
  - routine, disease stage and eligibility for conservative treatment and, 918
  - tumor size and death rate and, 2114

- Mantle cell lymphoma  
 autologous stem cell transplant for, outcome of, 2630  
 $\beta_2$  microglobulin in, prognosis and, 2630
- Mass spectrometry, laser desorption/ionization time-of-flight, in  
 prostate cancer, for biomarker discovery, 2576
- Mastectomy  
 vs. breast conservation therapy, for early stage cancer, 697  
 ductal lavage in, diagnostic sensitivity of, 2170  
 lymphedema after  
 laser therapy for, 1114  
 in long-term survivors, 679  
 preoperative MRI in, 468  
 prophylactic, reoperation after, 2152  
 skin-sparing, 2316
- Mathematical modeling, for cervical cancer, 2003
- Matriptasell/MT-SP1*, in cervical cancer, 1898
- Matrix metalloproteinase-2, in thymic cancer, prognosis and,  
 1822
- Mediastinal irradiation, for esophageal cancer, after heart trans-  
 plant, 2738 (letter)
- Medicolegal issues, 1555
- Medulloblastoma  
 desmoplastic, in nevoid basal cell carcinoma syndrome, 618  
 dietetic intervention in, 1014  
 MYC target genes in, 841
- Megestrol acetate, adrenal suppression and, in children, 397
- Melanocytic nevi, translation initiation factor eIF-2 $\alpha$ , 1080
- Melanoma  
 in familial atypical multiple-mode melanoma-pancreatic car-  
 cinoma syndrome, phenotype in, 798  
 lymph node metastasis in, vascular endothelial growth factor-  
 C and, 789  
 plasmid DNA vaccine for, 144  
 psychological distress in, cognitive-behavioral interventions  
 for, 854  
 signs and symptoms of, Breslow depth and, 344  
 tamoxifen for, 1355  
 thin cutaneous, prognosis of, 1223  
 translation initiation factor eIF-2 $\alpha$ , 1080
- Melphalan, for extremity soft tissue sarcoma, 1483
- MEN1*, in poorly differentiated endocrine carcinomas, 1273
- Meningeal involvement, in neuroblastoma, 155
- Meningiomas, benign skull base, radiotherapy for, 1473
- Menstrual cycling, dietary fat/fiber and, 1870
- Mesna, with ifosfamide and granulocyte-colony-stimulating  
 factor, for mesothelioma, 331
- Mesothelioma, unresectable, ifosfamide with mesna and granu-  
 locyte-colony-stimulating factor for, 331
- Metachronous osteosarcoma, posttreatment, 2457
- <sup>131</sup>I-Metaiodobenzylguanidine, for malignant pheochromocy-  
 toma, 239
- Metaiodobenzylguanidine, radiolabeled, for neuroblastoma,  
 thyroid protection for, 389
- Metastasis  
 central nervous system, in neuroblastoma, 155  
 cerebral  
 in esophageal cancer, 1925  
 in neuroblastoma, 155  
 in prostate cancer, 363  
 in thyroid cancer, 356  
 choroid, clinical features and treatment of, 1232  
 hepatic  
 in colorectal cancer, hepatic cryotherapy and regional che-  
 motherapy for, 320  
 percutaneous radiofrequency ablation of, 2303 (letter)  
 lymph node  
 in breast cancer  
 Bcl-2 and p53 in, 2554  
 in nonsentinel nodes, 2307  
 tumor size and, 1569  
 mechanisms of, 413  
 in melanoma, vascular endothelial growth factor-C and,  
 789  
 in nonsmall cell lung cancer, vascular endothelial growth  
 factor-C and, 1217  
 in papillary microcarcinoma of thyroid, 31  
 in thyroid cancer, 712  
 occult, in ductal carcinoma in situ, 2083 (editorial), 2105  
 skeletal  
 bisphosphonates and radiotherapy for, 1318  
 in breast cancer, zoledronic acid vs. pamidronate disodium  
 for, 1735  
 in multiple myeloma, zoledronic acid vs. pamidronate di-  
 sodium for, 1735  
 osteolytic, bisphosphonates and radiotherapy for, 1318  
 in renal cell carcinoma, zoledronic acid for, 962  
 in thyroid cancer, 712  
 Methimazole, in radiation protection of thyroid, 389  
 Methotrexate  
 for breast cancer, responsiveness to, *erbB2* overexpression  
 and, 1123  
 for Burkitt lymphoma, in HIV infection, 1196  
 for Hodgkin disease, with radiotherapy, 2393  
 Mexican Americans. *See also* Race/ethnicity  
*XRCC3* polymorphism in, lung cancer risk and, 1701  
*MHL1*, in synchronous colorectal cancers, 48  
 Microsatellite instability  
 in ovarian cancer, mismatch repair defects and, 2091 (edito-  
 rial), 2199  
 in small intestinal cancer, 1774 (letter)  
 in synchronous colorectal cancers, 48  
 Mismatch repair defects, in ovarian cancer, 2091 (editorial), 2199  
 Mitomycin, for nonsmall cell lung cancer, vs. gemcitabine-car-  
 boplatin, 542  
 MLH1, in small intestinal cancer, 1774 (letter)  
 Mood disturbances, in stem cell transplantation, music therapy  
 for, 2723  
 Motility-related protein-1, in bladder cancer, prognosis and,  
 1649  
 MSH2  
 in small intestinal cancer, 1774 (letter)  
 in synchronous colorectal cancers, 48  
 MUC5AC mucin, in cholangiocarcinoma, prognosis and, 1438  
 Mucositis  
 chemotherapy-induced, 1531  
 oral, pain assessment for, 406  
 Multidrug resistance protein 1, in osteosarcoma, reduced folate  
 carrier protein and, 1947  
 Multiple myeloma  
 bone metastases in, zoledronic acid vs. pamidronate diso-  
 dium for, 1735  
 PEG L-asparaginase for, 94  
 Multiple primaries, brain tumors and, 562  
 Music therapy, in autologous stem cell transplantation, 2723  
 Mycosis fungoides, juvenile-onset, outcome in, 2282  
 Mycotic infections, in aplastic anemia, 86  
 MYC target genes, in neuroblastoma, 841

Myelodysplastic syndrome  
 sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor in, 2410  
 soluble CD86 in, prognosis and, 1681  
 Myeloid metaplasia, agnogenic, interferon for, 100  
 Myeloproliferative disorders, interferon for, 100  
 Myocardial infarction, reduced risk for, in elderly breast cancer survivors, 2

## N

Nasolacrimal duct obstruction, docetaxel and, 504  
 Nasopharyngeal cancer  
 Epstein-Barr virus DNA in, prognosis and, 288  
<sup>18</sup>F-fluoro-2-deoxyglucose positron emission tomography, vs. magnetic resonance imaging, 283  
 mucosal recurrent, latent membrane protein 1 gene in swab specimens in, 2385  
 radiotherapy alone for, 74  
 National Cancer Data Base report, on osteosarcoma of head and neck, 1670  
 Native Americans. *See also* Race/ethnicity  
 cancer rates among, 1262  
 Nausea and vomiting, chemotherapy-induced  
 assessment tool for, 645  
 palonosetron prophylaxis for, 2473  
 NCOA3, in breast cancer, prognosis and, 18  
 Nephrectomy, for renal cell carcinoma, with immunotherapy, survival prediction for, 2566  
 Neuroblastoma  
 in adolescents, 349  
 CNS metastases in, 155  
 MYC target genes in, 841  
 N-myc and C-myc in, 841  
 radiolabeled metaiodobenzylguanidine for, thyroid protection for, 389  
 recurrent/refractory, topotecan, vincristine, and doxorubicin for, 2488  
 revised international classification of, 2274  
 Neurocomputational model, in prostate cancer screening, 1849  
 Neuroendocrine head and neck cancer, nonsinonasal, management of, 2322  
 Neuropilin-1, in pancreatic cancer, 720  
 Neurotoxicity, of taxanes, 822  
 Neutropenia  
 in breast cancer, prophylactic filgrastim for, risk model for, 222  
 febrile, requiring hospitalization  
 in CHOP, CHOP-2, or CNOP chemotherapy, 2402  
 imipenem and cefepime for, 1039  
 in non-Hodgkin lymphoma, 2402  
 Nevod basal cell carcinoma syndrome, desmoplastic medulloblastoma in, 618  
 Nevus, melanocytic, translation initiation factor eIF-2 $\alpha$ , 1080  
 Nicotine dependence. *See also* Smoking  
 treatment of, in cancer patients, 632  
 N-myc, in neuroblastoma, 841  
 Nodal metastasis. *See* Lymph node metastasis  
 Nodular ganglioneuroblastoma, prognostic subsets in, 2274  
 Nongerminomatous intracranial malignant germ cell tumors, 369  
 Non-Hodgkin lymphoma. *See* Lymphoma  
 Nonsinonasal neuroendocrine head and neck cancer, management of, 2322  
 Non-small cell lung cancer. *See* Lung cancer

Nuclear pleomorphism, in skull base/non-skull base chordomas, prognosis and, 1934  
 Numbness, in long-term breast cancer survivors, 679  
 Nutrition. *See* Diet  
 Nutritional support  
 in medulloblastoma, 1014  
 megestrol acetate in, adrenal suppression due to, in children, 397  
 in supratentorial primitive neuroectodermal tumors, 1014

## O

Obesity  
 cervical cancer and, 814  
 esophageal cancer and, 940  
 gastric cancer and, 940  
 treatment-related toxicity in colon cancer and, 484  
 Ocular adnexa, MALT lymphoma of, radiotherapy for, 865  
 Oligodendrogliomas, COX-2 in, prognosis and, 1465  
 Oncologists  
 attitudes of toward complementary and alternative medicine, in Japan, 2302 (letter)  
 attitudes of toward palliative care, 2502  
 minority, increasing the pool of, 2736 (letter)  
 Oophorectomy, prophylactic, morphologic and immunohistochemical findings in, 2599  
 Opportunistic infections  
 in aplastic anemia, 86  
 risk of, with hospitalized SARS patient, 2739  
 Optical imaging, in cervical cancer, 2015  
 Oral cancer. *See also* Head and neck cancer  
 pathologic vs. clinical lymph node staging in, 508  
 recurrent, [<sup>18</sup>F]-2-fluorodeoxyglucose positron emission tomography in, 2257  
 Oral mucositis, pain assessment for, 406  
 Oropharyngeal cancer, UGT1A10 polymorphisms in, 872  
 Osteogenic sarcoma. *See* Osteosarcoma  
 Osteolytic bone metastases. *See also* Skeletal metastasis  
 bisphosphonates and radiotherapy for, 1318  
 Osteopontin, in hepatocellular cancer, prognosis and, 119  
 Osteosarcoma  
 chemosensitivity of, P-glycoprotein and, 581  
 contemporary chemotherapy for, outcome after, 2447  
 familial, 1947  
 of head and neck, National Cancer Data Base report on, 1670  
 posttreatment metachronous tumors after, 2457  
 recurrent, ecteinascidin 743 for, 832  
 reduced folate carrier protein in, chemosensitivity and, 1947  
 Ovarian cancer  
 basement membrane loss in, 2607  
 bikunin gene expression in, prognosis and, 424  
 BRCA1 mutations and, in non-Jewish Spanish-Americans, 597  
 Disabled-2 in, 2607  
 docetaxel and pegylated liposomal doxorubicin for, 610  
 endometriosis-associated, 1658  
 HER-2 overexpression in, prognosis and, 66  
 mismatch repair defects in, 2091 (editorial), 2199  
 prophylactic oophorectomy for, 2599, 2607  
 survivors of, quality of life in, 1061  
 topotecan for, in three-day regimen, 1664  
 tumorigenesis in, 2599, 2607  
 tumor vascularity in, COX-2 and, 1423  
 tyrosine kinases in, 758  
 Ovarian surface epithelium, preneoplastic changes in, 2599, 2607  
 Oxaliplatin, gencitabine plus, 2664

## P

- p16  
 in cervical cancer, 1880  
 in poorly differentiated endocrine carcinomas, 1273
- p21, in cervical cancer, prognosis and, 1880
- p21<sup>Cip1</sup>, in breast cancer, chemosensitivity and, 1123
- p27, in cervical cancer, prognosis and, 1880
- p34<sup>Cdc2</sup>, hyperphosphorylation of, in breast cancer, chemosensitivity and, 1123
- p53  
 in basal cell carcinoma, prognosis and, 2708  
 in breast cancer, in primary tumor and metastatic nodes, prognosis and, 2554  
 in early-onset breast cancer, in Korean v. white woman, 1587  
 in poorly differentiated endocrine carcinomas, 1273
- Paclitaxel  
 for breast cancer, with trastuzumab, for angiogenesis inhibition, 1377  
 for esophageal cancer, with radiotherapy, 2177  
 for nonsmall cell lung cancer, 1707  
 in patients >70 years, 779  
 for paranasal sinus cancer, 2214  
 for prostate cancer, 269, 1842, 2192
- Pain assessment, for oral mucositis, 406
- Palliative care, oncologists' attitudes toward, 2502
- Palliative surgery, resource utilization after, vs. after curative surgery, 2266
- Palonosetron, prophylactic, for nausea and vomiting, 2473
- Pamidronate disodium, for bone metastasis, in myeloma/breast cancer, vs. zoledronic acid, 1735
- Pancreatic cancer  
 CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells in, 1089  
 in familial atypical multiple-mode melanoma-pancreatic carcinoma syndrome, phenotype in, 798  
 neuropilin-1 in, 720
- Pancreatic gastrinomas, immunophenotype of, 1967
- Papanicolaou smear  
 adherence with, behavioral factors in, 2009  
 nurse's role in, 2009
- Papillary microcarcinoma of thyroid, outcome in, 31
- Papillary thyroid cancer  
 pure vs. follicular, 1997 (letter)  
 tall cell variant, c-Met expression in, 1386
- Paraganglioma, high-dose <sup>131</sup>I-metaiodobenzylguanidine for, 239
- Paranasal sinus cancer, cisplatin, Paclitaxel and ifosfamide for, 2214
- Parathyroid cancer, radiotherapy for, 2378
- Parenteral nutrition. *See* Nutritional support
- Pathologic fractures, in long-term Ewing sarcoma survivors, 2687
- PCA-24, in prostate cancer, prognosis and, 2576
- PEG L-asparaginase, for multiple myeloma, 94
- Pegylated liposomal doxorubicin  
 for cutaneous T-cell lymphoma, 993  
 with docetaxel, for advanced cancer, 610
- Pelvic exenteration, for cervical cancer, 2052
- Percutaneous radiofrequency ablation therapy  
 for hepatocellular carcinoma, 433 (letter)  
 for liver metastases, 2303 (letter)
- Peripheral blood progenitor cell autograft, for Hodgkin disease, 983
- Peripheral neuropathy  
 in long-term breast cancer survivors, 679  
 taxane toxicity and, 822
- P-glycoprotein, in osteosarcoma, chemosensitivity and, 581
- Pharyngeal wall cancer, radiation therapy for, with/without planned neck dissection, 2224
- Phase I trials, expectations of benefit from, 166
- Pheochromocytoma, high-dose <sup>131</sup>I-metaiodobenzylguanidine for, 239
- Photodynamic therapy, intratumoral, in refractory solid tumors, 1767
- Photonics, in cervical cancer, 2015
- Physical activity  
 ductal carcinoma in situ risk and, 2161  
 for fatigue, 1786
- Physicians. *See* Oncologists; Primary care physicians
- Pigmentation abnormalities, imatinib mesylate-induced, 2483
- Pioglitazone, for advanced malignant vascular tumors, 2251
- Plasmid DNA vaccine, for melanoma, 144
- Platelet-derived endothelial cell growth factor, in renal cell carcinoma, 730
- Platelet-derived growth factor receptor- $\beta$ , in ovarian cancer, 758
- Pleomorphic extremity sarcoma, myoid differentiation in, prognosis and, 805
- Pleural effusion, in chronic lymphocytic leukemia, 1912
- Pneumonia, in chronic lymphocytic leukemia, 1912
- Polycythemia rubra vera, interferon for, 100
- Polyethylene glycol-conjugated L-asparaginase, for multiple myeloma, 94
- Polyps, endometrial, tamoxifen-related, K-ras mutations in, 1890
- Positron emission tomography  
 in nasopharyngeal cancer, 283  
 in recurrent oral squamous cell carcinoma, 2257
- Posttraumatic stress disorder, in long-term breast cancer survivors, 679
- Potassium iodide, in radiation protection of thyroid, 389
- Prednisone  
 for non-Hodgkin lymphoma, hospitalization for febrile neutropenia and, 2402  
 for prostate cancer, 1603
- Pregnancy  
 after breast cancer, survival and, 1131  
 breast cancer during, 1055
- Primary care physicians, mammography for older women and, 1811
- Primitive neuroectodermal tumors, supratentorial, dietetic intervention in, 1014
- Progesterone, dietary fat/fiber and, 1870
- Progesterone receptor(s)  
 in breast cancer  
 with early onset, in Korean v. white woman, 1587  
 after withdrawal of hormone replacement therapy, 2539  
 in endometriosis-associated ovarian cancer, 1658  
 endometriosis-associated ovarian cancer and, 1658
- Prognostic factors. *See* specific factors and cancers
- Polymorphic leukemia, alemtuzumab for, 773
- Prostate cancer  
 androgen-independent, cyclophosphamide, prednisone and diethylstilbestrol for, 1603  
 after benign prostatic hyperplasia, 1727  
 brain metastasis in, 363  
 carboplatin for, 269, 1842  
 core needle biopsy in, as predictor of PSA recurrence in, 2344  
 cyclophosphamide and dexamethasone for, in metronomic therapy, 1643  
 diagnosis of, 1169  
 docetaxel for



- with ketoconazole, 1855
  - with weekly administration, 1627
  - estramustine for, 269, 1842, 2192
  - etoposide for, 269, 2192
  - familial, genetic polymorphisms of estrogen receptor alpha, *CYP19*, and catechol-*O*-methyltransferase in, 1411
  - frequency of postdiagnosis PSA testing in, racial disparities in, 496
  - Gleason score 7, prognosis in, 2560
  - HERV-E in, 187
  - hormone-refractory
    - chemotherapy and immunotherapy for, 2592
    - combination chemotherapy for, 2088 (editorial), 2192
    - TEEC regimen for, 269
    - weekly chemotherapy for, 2192
  - hormone therapy for, number-needed-to-treat analysis of, 2351
  - nuclear structure alterations in, prognosis and, 2583
  - paclitaxel for, 269, 1842
  - PCA-24 in, prognosis and, 2576
  - predictive modeling for, 1417
  - presentation of, 1169
  - PSA-negative metastatic, clinical features of, 2362
  - radiation therapy for
    - brachytherapy, Patterns of Care study of, 1987
    - late genitourinary/gastrointestinal toxicity and, 949
  - recurrent, nuclear structure alterations in, prognosis and, 2583
  - screening for, 1169
    - neurocomputational model for, 1849
  - staging of, 1169
  - 3D conformal radiotherapy for, quality of life after, 2335
  - Prostate specific antigen
    - in diagnosis and staging, 1169
    - postdiagnosis testing of, racial disparities in, 496
    - in screening, neurocomputational model for, 1849
  - Proteolipid 1, in leiomyosarcoma, 1029
  - Proteomics, in prostate cancer, for biomarker discovery, 2576
  - Psychological distress. *See also* Quality of life
    - in autologous stem cell transplantation, music therapy for, 2723
    - fatigue and, 198
    - in melanoma, cognitive-behavioral interventions for, 854
    - in ovarian cancer survivors, 1061
  - Psychosocial factors, in breast cancer survival, in African Americans vs. whites, 1299
  - Pulmonary complications, in chronic lymphocytic leukemia, 1912
  - Pulmonary toxicity, of bleomycin/gemcitabine, for Hodgkin disease, 978
- Q**
- Quality of life
- in cervical cancer, behavioral factors in, 2009
  - fatigue and, 198, 1786
  - of female colorectal cancer survivors, 1749
  - of long-term breast cancer survivors, 679
  - nausea and vomiting and, assessment tool for, 645
  - of ovarian cancer survivors, 1061
  - in prostate cancer, after 3D conformal radiotherapy, 2335
- R**
- Race/ethnicity
- brain tumor survival and, 603
  - breast cancer survival and, 894, 908
    - psychosocial factors in, 1299
  - cancer rates among American Indians and Alaskan Natives and, 1262
  - endometrial cancer outcome and, 176
  - frequency of postdiagnosis PSA testing and, 496
  - head and neck cancer outcome after radiotherapy and, 2467
  - immunohistochemical biomarkers and HER-2/*neu* gene amplification in, early-onset breast cancer and, 1587
  - increasing the number of minorities in oncology and, 2736 (letter)
  - mammographic breast density and, 590
  - XRCC3* polymorphism in, lung cancer risk and, 1701
  - Radiation protection, thyroid, 389
  - Radiation therapy
    - anemia in, erythropoietin- $\alpha$  for, 1072
    - for angiosarcoma of scalp, 1716
    - for basal cell carcinoma, 2708
    - for benign skull base meningiomas, 1473
  - brachytherapy, for prostate cancer
    - late genitourinary/gastrointestinal toxicity and, 949
    - Patterns of Care study of, 1987
  - for breast cancer
    - with isolated supraclavicular recurrence, 11
    - lung cancer after, 1331 (editorial), 1364, 1457
    - vs. mastectomy, in early stage disease, 697
    - routine mammography and, 918
    - thyroid cancer after, 1309
    - utilization rate for, 1977
  - for central nervous system lymphoma, with bromodeoxyuridine, 1021
  - for cervical cancer, 2052
    - with concurrent chemotherapy and hyperthermia, 277
    - venous thrombosis and, 1514
  - with chemotherapy. *See* Chemoradiation
  - for choroid metastasis, 1232
  - for clear cell ependymoma, 2232
  - for endometrial cancer, in elderly, 2368
  - for glioblastoma
    - long-term survival in, 1745
    - salvage therapy for, 2678
  - for glottic cancer, 765
  - for head and neck cancer, racial factors in outcome of, 2467
  - intensity-modulated, level of use of, 204
  - for low-grade gliomas, in children, 1243
  - for MALT lymphoma, of ocular adnexa, 865
  - mediastinal, for esophageal cancer after heart transplant, 2738 (letter)
  - for nasopharyngeal cancer, 74
  - for nongerminomatous intracranial malignant germ cell tumors, 369
  - for nonsinonasal neuroendocrine head and neck cancer, 2322
  - for osteolytic bone metastases, 1318
  - outcome in, educational level and, 1497
  - for parathyroid cancer, 2378
  - for pharyngeal wall cancer, with/without planned neck dissection, 2224
  - for prostate cancer
    - late genitourinary/gastrointestinal toxicity and, 949
    - quality of life after, 2335
  - for rectal cancer palliation, with/without hyperthermia, 1759
  - for thyroid cancer, breast cancer after, 1309
  - thyroid protection in, 389

- Radical prostatectomy, PSA recurrence after, core needle biopsy as predictor of, 2344
- Radical trachelectomy, for cervical cancer, 2052
- Radiofrequency ablation therapy
- for breast cancer, followed by delayed surgical excision, 1369
  - for hepatocellular carcinoma, 433 (letter)
- Radioimmunoassay, for thyroglobulin, vs. immunoradiometric assay, 41
- Radiolabeled metaiodobenzylguanidine, for neuroblastoma, thyroid protection for, 389
- RANK/RANKL, in hematologic disorders, 458
- Rasburicase, for hyperuricemia, 1048
- Rb protein, in poorly differentiated endocrine carcinomas, 1273
- Recombinant granulocyte-colony-stimulating factor, with ifosfamide and mesna, for mesothelioma, 331
- Recombinant human erythropoietin
- for anemic patients receiving chemoradiation, 1072
  - for cervical cancer, venous thrombosis and, 1514
  - for fatigue, 1786
- Recombinant urate oxidase, for hyperuricemia, 1048
- Rectal bleeding, after brachytherapy for prostate cancer, 949
- Rectal cancer. *See also* Colorectal cancer
- reirradiation and hyperthermia for, 1759
- Rectal mucosal cell proliferation, diet and, 1161
- Reduced folate carrier protein, in osteosarcoma, chemosensitivity and, 1947
- Reflux, esophageal/gastric cancer risk and, 940
- REG, in gastric cancer, prognosis and, 1394
- Renal cell carcinoma
- clinical trials for, response assessment classification in, 1611
  - irinotecan for, 61
  - metastatic, nephrectomy and immunotherapy for, survival prediction for, 2566
  - thymidine phosphorylase/platelet-derived endothelial cell growth factor in, 730
  - TNM classification of, reassessment of, 2329
  - vinblastine and estramustine for, 1837
- Research studies. *See also* Clinical trials
- disclosure of "new findings" to candidates for, 885
- Resource utilization, after curative vs. palliative surgery, 2266
- Respiratory tract, chromium accumulation in, in chromate workers, 2420
- Retinoblastoma, extraocular, treatment and outcome in, 1292
- Retroperitoneal node dissection, for sex-cord stromal tumors, 753
- Rhabdomyosarcoma, adult, 571
- Rhenium sulfide, in sentinel node mapping, in esophageal cancer, 932
- Rituximab, for recurrent Hodgkin disease, 310
- Rofecoxib, for advanced malignant vascular tumors, 2251
- S**
- Salvage therapy, for glioblastoma, 2678
- Sarcoma. *See also specific types*
- familial, 1947
- SARS, hospitalization for, infection control issues in, 2739
- Scalp, angiosarcoma of, 1716
- Screening
- for bladder cancer, fibroblast growth factor receptor 3 mutations in, 737
  - for breast cancer
    - breast density on, racial differences in, 590
    - in initial vs. recurrent disease, 1596
    - in older women, primary physicians' role in, 1811
    - primary physicians' role in, 1811
    - routine, disease stage and eligibility for conservative treatment and, 918
    - tumor size and death rate and, 2114
- for cervical cancer
- adherence with, behavioral factors in, 2009
  - nurse's role in, 2009
- for lung cancer, smoking abstinence after, 2495
- for prostate cancer, 1169
- neurocomputational model for, 1849
- Seminoma, advanced, treatment and prognostic factors in, 745
- Sentinel nodes. *See also* Lymph node(s)
- biopsy of
    - in breast cancer, short-term morbidity of upper limb after, 690
    - in ductal carcinoma in situ, 2083 (editorial)
    - in breast cancer, intraoperative immunofluorescent evaluation of, 1562
    - dissection of, in cervical cancer, 2514 (letter)
    - mapping of, in esophageal cancer, 932
- Serum endostatin, in hepatocellular carcinoma, tumor vascularity and, 1101 (letter)
- Severe acute respiratory syndrome (SARS), hospitalization for, infection control issues in, 2739
- Sex-cord stromal tumors, retroperitoneal node dissection for, 753
- Sex hormones, dietary fat/fiber and, 1870
- Sexual rehabilitation, in cervical cancer, 2009
- Skeletal metastasis
- bisphosphonates and radiotherapy for, 1318
  - in breast cancer, zoledronic acid vs. pamidronate disodium for, 1735
  - in multiple myeloma, zoledronic acid vs. pamidronate disodium for, 1735
  - osteolytic, bisphosphonates and radiotherapy for, 1318
  - in renal cell carcinoma, zoledronic acid for, 962
- Skin cancer, basal cell, superficial radiotherapy for, 2708
- Skin hypopigmentation, imatinib mesylate-induced, 2483
- Skin-sparing mastectomy, 2316
- Skull base chordomas, nuclear pleomorphism in, prognosis and, 1934
- Skull base meningiomas, 1473
- benign, radiotherapy for, 1473
- Skull base tumors, craniofacial surgery for, 1179
- Small cell lung cancer. *See* Lung cancer
- Small intestinal cancer, microsatellite instability and MLH1 and MSH2 expression in, 1774 (letter)
- Smoking
- abstinence from after lung cancer screening, 2495
  - cessation strategies for, in cancer patients, 632
  - lung cancer in breast cancer survivors and, 1457
  - oropharyngeal cancer and, *UGT1A10* polymorphisms and, 872
- Social networks, female colorectal cancer survival and, 1749
- Socioeconomic status, survival and, 1497
- Soft tissue sarcoma
- familial, 1947
  - pleomorphic extremity, myoid differentiation in, prognosis and, 805
  - single nucleotide polymorphism in fibroblast growth factor receptor 4 and, prognosis and, 2245
  - temozolomide for, 1942, 2693
- Soluble tumor necrosis factor, in acute lymphoblastic leukemia, prognosis and, 625
- Somatostatin, cytotoxic analogues of, for gastric cancer, 1401

Spanish-Americans, non-Jewish, *BRCA1* mutations in, 597  
Spectrometry, laser desorption/ionization time-of-flight, in prostate cancer, for biomarker discovery, 2576  
Spinal cord, malignant astrocytoma of, 554  
Spinal metastases, in neuroblastoma, 155  
Spiral chest computed tomography, in lung cancer screening, smoking abstinence after, 2495  
Squamous cell carcinoma, of head and neck. *See* Head and neck cancer  
Staging  
*AJCC Cancer Staging Manual* for, classification of isolated tumor cells in, 2741  
of hepatoblastoma, 668  
pathologic vs. lymph node, in tongue cancer, 508  
of prostate cancer, 1169  
Stem cell transplantation  
for breast cancer, candidemia and, 25  
for chronic myelogenous leukemia, 81, 437  
for Hodgkin disease, 983  
for mantle cell lymphoma, outcome of, 2630  
music therapy in, 2723  
Steroid receptor coactivators and corepressors, in endometrial hyperplasia/carcinoma, 2207  
Steroids. *See also* Prednisone  
with megestrol acetate, in children, 397  
Stomach cancer. *See* Gastric cancer  
Stomatitis, pain assessment for, 406  
Supratentorial primitive neuroectodermal tumors, dietetic intervention in, 1014  
Surgery. *See also specific procedures and cancers*  
curative vs. palliative, resource utilization after, 2266  
for skull base tumors, 1179  
Syndecan-1, in breast cancer, prognosis and, 474  
Synovial sarcoma, diagnosis of, molecular testing in, 2700  
*SYT-SSX* fusion transcripts, in synovial sarcoma, 2700

## T

TADG-15, in cervical cancer, 1898  
Talaporfin sodium, intratumoral photoactivation of, in refractory solid tumors, 1767  
Tall cell variant papillary thyroid cancer, c-Met expression in, 1386  
Tamoxifen  
cardioprotective effects of, 2  
endometrial polyps and, *K-ras* mutations in, 1890  
for melanoma, 1355  
secondary ultrasonographic endometrial thickening and, 431 (letter)  
Taxanes, toxicity of, measurement of, 822  
Tc-99m colloidal rhodium sulfide, in sentinel node mapping, in esophageal cancer, 932  
T-cell lymphoma. *See* Lymphoma  
T cells, CD4<sup>+</sup>CD25<sup>+</sup> regulatory, in gastrointestinal cancer, 1089  
Telomerase, in cervical cancer, 2064  
Telomere length, in hepatocellular cancer, prognosis and, 110  
Temozolomide  
for gastrointestinal stromal tumors, 2693  
for soft tissue sarcoma, 1942, 2693  
Tenascin-C, in brain tumors, prognosis and, 2430  
Teniposide, for extraocular retinoblastoma, 1292  
Terminal disease, palliative care in, oncologists' attitudes toward, 2502

Testicular cancer  
advanced seminomatous, treatment and prognostic factors in, 745  
germ cell, with elevated tumor markers, salvage surgery for, 1635  
in sex-cord stromal tumors, retroperitoneal node dissection for, 753  
*TFAP2C*, in breast cancer, prognosis and, 18  
*TFF1*, in gastric cancer, 2184  
32-kilodalton and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein, in adenocarcinoma, 1547  
Thrombosis, venous  
in breast cancer, 1578  
in central nervous system lymphoma, 1239  
in cervical cancer, 1514  
Thymic cancer  
matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in, prognosis and, 1822  
weekly chemotherapy with CODE regimen for, 926  
Thymidine phosphorylase, in renal cell carcinoma, 730  
Thyroglobulin, in thyroid cancer, discordant radioimmunoassay vs. immunoradiometric assay results for, 41  
Thyroid, radiation protection of, 389  
Thyroid cancer  
brain metastasis in, 356  
metastasis in, 712  
papillary  
microcarcinoma, outcome in, 31  
pure vs. follicular, 1997 (letter)  
tall cell variant, c-Met expression in, 1386  
radiotherapy for, breast cancer after, 1309  
serum thyroglobulin results in, 41  
Thyroxine, in radiation protection of thyroid, 389  
Tissue inhibitor of metalloproteinase-2, in thymic cancer, prognosis and, 1822  
TNM classification. *See also* Staging  
of isolated tumor cells in, 2741  
of renal cell carcinoma, reassessment of, 2329  
Tongue cancer, pathologic vs. clinical lymph node staging in, 508  
*TOP1*, in breast cancer, prognosis and, 18  
Topotecan  
for neuroblastoma, 2488  
for ovarian cancer, in 3-day regimen, 1664  
Total parenteral nutrition. *See* Nutritional support  
*TRAIL*, in hematologic disorders, 458  
Transitional cell carcinoma  
of bladder. *See* Bladder cancer  
of upper urinary tract  
bladder and contralateral UUT tumors after, 1620  
endoscopic management of, 55  
of urothelial tract, gemcitabine and docetaxel for, 1863  
Translation initiation factor eIF-2 $\alpha$ , in melanocytic and colonic epithelial tumors, 1080  
Transplantation  
heart, esophageal cancer after, mediastinal irradiation for, 2738  
liver, for hepatoblastoma, 668  
stem cell  
for breast cancer, candidemia and, 25  
for chronic myelogenous leukemia, 81, 437  
for Hodgkin disease, 983  
for mantle cell lymphoma, outcome of, 2630  
music therapy in, 2723

Trastuzumab, with paclitaxel, for breast cancer, for angiogenesis inhibition, 1377  
Trefol factor 1 transcript, in gastric cancer, 2184  
Trimodal spectroscopy, in cervical cancer, 2015  
Trofosfamide, metronomic, for advanced malignant vascular tumors, 2251  
*TSLC1*, in lung cancer, clinical/prognostic significance of, 1002  
Tumor-associated differentially expressed gene-15, in cervical cancer, prognosis and, 1898  
Tumor cells, isolated, TNM classification of, 2741  
Tumor lysis syndrome, rasburicase prophylaxis for, 1048  
Tumor necrosis factor- $\alpha$ , for extremity soft tissue sarcoma, 1483  
Tumor necrosis factor, soluble 55-kilodalton isoform of, in acute lymphoblastic leukemia, prognosis and, 625  
Tumor necrosis factor superfamily, in hematologic disorders, 458  
Tyrosine kinases, in ovarian cancer, 758

## U

UDP-glucuronosyltransferase superfamily, oropharyngeal cancer and, 872  
*UGT1A10* polymorphisms, oropharyngeal cancer and, 872  
Ulcers, oral, pain assessment for, 406  
Ultrasound surveillance, for endometrial cancer, in women at risk for hereditary nonpolyposis colorectal cancer, 1772 (letter)  
Upper limb  
  complications in, from axillary/sentinel node biopsy, in breast cancer, 690  
  lymphedema of  
    laser therapy for, 1114  
    in long-term breast cancer survivors, 679  
Upper urinary tract, primary transitional cell carcinoma of, bladder and contralesional UUT tumors after, 1620  
Urate oxidase, for hyperuricemia, 1048  
Urethral toxicity, of brachytherapy, in prostate cancer, 949  
Urine sediment DNA, fibroblast growth factor receptor 3 mutations in, in bladder cancer, 737  
Urokinase-type plasminogen activator, in bladder cancer, 1995 (letter)  
Urothelial cancer, gemcitabine and docetaxel for, 1863

## V

Vaccines  
  for cervical cancer, 2044, 2064  
  plasmid DNA, for melanoma, 144  
Vascular endothelial growth factor  
  in breast cancer, therapeutic efficacy and, 2125  
  endometriosis-associated ovarian cancer and, 1658  
  in melanoma, lymph node metastasis and, 789  
  neuropilin-1 and, in pancreatic cancer, 720  
  in nonsmall cell lung cancer, nodal metastasis and, 1217  
Venous thrombosis  
  in breast cancer, 1578  
  in central nervous system lymphoma, 1239  
  in cervical cancer, 1514  
Vinblastine  
  for Hodgkin disease, 978  
  with radiotherapy, 2393  
  for nonsmall cell lung cancer, vs. gemcitabine-carboplatin, 542  
  for renal cell cancer, 1837  
Vincristine  
  for extraocular retinoblastoma, 1292  
  for neuroblastoma, 2488  
  for non-Hodgkin lymphoma, hospitalization for febrile neutropenia and, 2402  
  for thymic cancer, 926  
Vinorelbine, for breast cancer palliation, 1325 (letter)  
Vomiting, chemotherapy-induced  
  assessment tool for, 645  
  palonosetron prophylaxis for, 2473  
Vulvar cancer, routine follow-up in, 2624

## X

*XRCC3* polymorphism, lung cancer risk and, in minority populations, 1701

## Z

Zoledronic acid, for bone metastasis  
  in myeloma/breast cancer, vs. pamidronate disodium, 1735  
  in renal cell carcinoma, 962  
Zollinger-Ellison syndrome, 1967  
  tumor burden changes in, serial chromogranin A and gastrin measurements for, 249

# Authors' Index—Volume 98

## A

Abeler, V. M., 1880  
 Abou-Saif, A., 249  
 Abrams, J., 1491  
 Abramson, A. F., 377  
 Abriani, L., 1786  
 Abruzzo, L. V., 310  
 Abu-Rustum, N., 2368  
 Acholonu, S. A., 2630  
 Adami, H.-O., 1727  
 Adinin, R. B., 504  
 Adjadj, É., 1309  
 Afif, C., 1039  
 Africano, N. L., 632  
 Aggarwal, A., 1855  
 Aggarwal, B. B., 458  
 Agnese, D. M., 1369  
 Agrawal, N. R., 94  
 Ahmadi, M. A., 504  
 Ahmed, S., 1912  
 Aihara, T., 1562  
 Akaza, H., 1635  
 Akhter, S., 2730  
 Akiyama, T., 1394  
 Albert, M., 949  
 Albertsen, P. C., 496  
 Albitar, M., 1681, 2657  
 Aldovini, D., 474  
 Alektiar, K. M., 2368  
 Alexander, H. R., 219  
 Alfsen, G. C., 1880  
 Ali-Fehmi, R., 1423  
 Allen, H. J., 1863  
 Allgäuer, M., 2678  
 Al-Othman, M. O. F., 2467  
 Altekruze, S. F., 814  
 Altemus, R. M., 697  
 Alvarez, R., 2075  
 Alvarez, R. D., 2044  
 Alvarez-Secord, A., 277  
 Amadori, S., 1786  
 Ambinder, R. F., 300  
 Ambrus, J. L., Jr., 2730  
 Ambrus, J. L., Sr., 2730  
 Amdur, R. J., 1473, 2224, 2467  
 Amin, M., 1055  
 Amlashi, S. F. A., 618  
 Amling, C. L., 2344  
 Amos, C. I., 1701  
 Anaissie, E. J., 315  
 Anderson, E., 2539  
 Anderson, H., 542  
 Anderson, P. R., 918  
 Anderson, S. N., 1114, 2743  
 Andreeff, M., 522, 888  
 Andreesen, R., 2251  
 Anfossi, S., 1898

Ang, K. K., 1497, 2322  
 Antimi, M., 337  
 Antman, K. H., 331  
 Antoneli, C. B. G., 1292  
 Aoyagi, Y., 110  
 Apffelstaedt, J., 1735  
 Apostolakis, L. W., 1670  
 Arbeit, J. M., 2064  
 Arbuckle, R., 504  
 Arias, V., 1292  
 Arisawa, K., 2671  
 Arndt, C. A. S., 2447  
 Arnold, P. G., 2152  
 Aronson, D. C., 668  
 Aronson, W. J., 2344  
 Arquette, M. A., 610  
 Arriagada, R., 1232  
 Arun, B., 2554  
 Asao, T., 932  
 Ascari, E., 2393  
 Asgharian, B., 249  
 Ashcroft, L., 542  
 Ashfaq, R., 2554  
 Ashley, D. M., 397  
 Assaraf, Y. G., 1958  
 Atkinson, J. L., 356  
 Au, G. K. H., 74  
 Au, S.-K., 31  
 Austin, M. A., 798  
 Axell, L., 597  
 Azuero, R., 187  
 Azzoni, C., 1273

## B

Baas, P., 690  
 Babaian, R. J., 1849  
 Babin-Boilletot, A., 349  
 Bachleitner, T., 2547  
 Bagatell, R., 832  
 Bagiella, E., 1942  
 Bai, L.-Y., 1188  
 Bajo, A. M., 1401  
 Baker, C., 1863  
 Baker, L. H., 331, 1716  
 Bakish, J., 1014  
 Balcerzak, S. P., Jr., 331  
 Baldinu, P., 1540  
 Bales, W. D., 2583  
 Ballard-Barbash, R., 1782  
 Baloch, Z. W., 1386  
 Balshem, A., 166  
 Bandou, E., 1394  
 Bang, Y.-J., 2651  
 Bansal, G., 1849  
 Barakat, R. R., 2368  
 Baranda, J., 1855  
 Barbareschi, M., 474  
 Bardou, V.-J., 1627  
 Barduagni, M., 337  
 Barker, J. L., Jr., 2322  
 Barnes, W. A., 814  
 Barnett, G. H., 1465  
 Barnholtz-Sloan, J. S., 603  
 Barqawi, A., 1643  
 Barrera, E., 1417  
 Bartenstein, P., 2257  
 Bartolini, S., 128  
 Barton, M., 1977  
 Barzan, L., 765  
 Basen-Engquist, K., 2009  
 Bashir, S., 249  
 Bassi, D., 1273  
 Bataille, F., 2251  
 Baumgart, U., 2678  
 Bayer, A., 2291  
 Beach, J., 2693  
 Beard, C., 949  
 Beccaglia, P., 1786  
 Becher, H., 894  
 Becker, K., 1521  
 Becker, L. E., 1243  
 Beckler, A., 1547  
 Beckler, A. D., 2184  
 Bedrosian, I., 468  
 Beer, T. M., 1417  
 Beex, L. V. A. M., 2125  
 Bégin, L. R., 1569  
 Begovic, M., 1362  
 Behm, F. G., 2715  
 Belch, A., 1735  
 Bell, M., 2075  
 Bell, M. C., 2044  
 Beldegrun, A., 2566  
 Bellone, S., 1898  
 Bénard, J., 155  
 Bendaly, J., 872  
 Benjamin, R. S., 2693  
 Benkö, T., 2291  
 Bennett, J. M., 100  
 Benson, A. B., III, 166, 484  
 Benton, C. L., 377  
 Benz, P., 2257  
 Berand, A., 2251  
 Berchuck, A., 277  
 Beresford, C., 542  
 Bergeron, C., 349  
 Berkey, B. A., 1497  
 Bernstein, L., 940, 2161  
 Berretta, M., 2440  
 Berté, R., 2393  
 Bertulli, R., 571  
 Berwick, M., 344  
 Betti, M., 128  
 Bhooipalam, N., 331  
 Bhudhisawasdi, V., 1438



- Biasotti, S., 2488  
 Bignon, Y.-J., 2599  
 Bignotti, E., 1898  
 Bihrie, R., 753  
 Birtle, A. J., 2362  
 Bjeldanes, L. F., 2511  
 Blaakaer, J., 66  
 Bladou, F., 1627  
 Bleicher, R. J., 2316  
 Blessing, J. A., 1664  
 Bloom, K. J., 1369  
 Blouin, P., 349  
 Blumenschein, G., Jr., 2214  
 Blumgart, L. H., 1689  
 Bobustuc, G., 363  
 Boccadoro, M., 983  
 Bock, A., 2678  
 Bock, J. E., 66  
 Bodey, G. P., 86, 292  
 Bodurka, D. C., 758, 2009  
 Bogdahn, U., 2678  
 Bohannon, R., 2335  
 Boige, V., 2664  
 Boktour, M. R., 1039  
 Boland, C. R., 2091  
 Boland, G. P., 2539  
 Boleslawski, E., 2664  
 Boltze, C., 1934  
 Bond, J. D., 397  
 Bondy, M. L., 1457  
 Bonyhay, L., 2664  
 Boonla, C., 1438  
 Boraas, M. C., 918  
 Bordi, C., 1273  
 Borneman, T., 2266  
 Bosly, A., 1048  
 Boss, E. A., 2028  
 Bosserman, L. D., 1863  
 Boswell, W., 144  
 Bottarelli, L., 1273  
 Böttcher, K., 1521  
 Botto, H., 970  
 Boudreau, D. M., 1504  
 Bouffet, E., 1014  
 Boyett, J. M., 1243  
 Bradley, P. K., 2070  
 Brady, M. S., 344  
 Brancaccio, L., 1707  
 Brannan, C., 222  
 Brassier, G., 618  
 Brawanski, A., 2678  
 Brawer, M. K., 1849  
 Brenner, P. C., 2560  
 Brentnall, T. A., 798  
 Brewer, M. A., 2015  
 Bridger, P. G., 1179  
 Brinton, L. A., 814  
 Brisse, H., 155  
 Bristow, R. E., 1658  
 Broadbush, R., 758  
 Brockmeyer, N. H., 993  
 Brogi, E., 2170  
 Broglia, C., 2393  
 Bron, D., 1048  
 Bross, K., 2251  
 Brostjan, C., 2291  
 Browning, M., 2657  
 Bruggers, C., 841  
 Brunet, J.-S., 1569  
 Bruns, C. J., 720  
 Bucana, C. D., 720  
 Buchholz, T. A., 1150, 1331  
 Buckner, J. C., 356  
 Bui, B. N., 2700  
 Bui, M. H. T., 2566  
 Bukowski, R. M., 94  
 Bulgakov, G., 1967  
 Buller, R. E., 2199  
 Bundred, N. J., 2539  
 Burak, W. E., 1141  
 Burak, W. E., Jr., 1369  
 Burg, G., 2708  
 Burger, P., 2232  
 Burger, P. C., 1243  
 Burgess, M. A., 2693  
 Burnett, C. B., 166  
 Burt, P. A., 542  
 Burt, R., 1161  
 Busch, J.-O., 993  
 Busch, R., 1521  
 Butts, J. A., 2192  
 Buzaglo, J., 2009  
 Buzby, G. P., 468  
 Buzdar, A., 229  
  
**C**  
 Cabanillas, F., 1021  
 Caffo, O., 474  
 Cai, J., 955  
 Cain, J., 737  
 Caine, G. J., 1578  
 Callans, L. S., 468  
 Calle, E. E., 2161  
 Camerlo, J., 1627  
 Cane, S., 1898  
 Canellos, G. P., 978  
 Cangi, M. G., 474  
 Cantor, S. B., 1531, 2003  
 Cantu, G., 1179  
 Caracciolo, D., 983  
 Carati, C. J., 1114, 2743  
 Carlson, M., 841  
 Carr-Locke, D. L., 949  
 Carroll, W. L., 841  
 Carter, D., 1587  
 Cartmell, A., 2473  
 Casabé, A. R., 262  
 Casadio, C., 2170  
 Casali, P. G., 571  
 Casanova, M., 571  
 Cassileth, B. R., 2723  
 Castel, L. D., 166  
 Castellano, T. M., 597  
 Castilla, E. A., 1465  
 Catalano, P. J., 484  
 Catane, R., 2502  
 Cavalli, C., 2393  
 Celeste, F., 262  
 Cella, D., 406, 822  
 Cerase, A., 1540  
 Ceribelli, A., 337  
 Chadha, K. C., 2730  
 Chambers, M., 1531  
 Champlin, R., 292  
 Champlin, R. E., 2410, 2630  
 Chan, A. T. C., 288  
 Chan, J. K. C., 31  
 Chan, L. Y. S., 288  
 Chang, A. E., 2307  
 Chang, H.-W., 1444  
 Changchien, C.-S., 1444  
 Chao, K. S. C., 2322  
 Chao, T.-C., 1188  
 Chapman, R. A., 331  
 Chapman, Y., 1863  
 Chappuis, P. O., 1569  
 Charu, V., 2473  
 Chatterton, R. T., 1870  
 Chay, C. H., 269  
 Che, M., 1423  
 Cheesman, A. D., 1179  
 Chen, B.-L., 1735  
 Chen, C., 1596  
 Chen, C.-L., 119  
 Chen, D.-T., 187  
 Chen, J. C., 1767  
 Chen, L. L., 2693  
 Chen, M.-H., 949  
 Chen, P.-M., 1188  
 Cheng, L., 1830  
 Cheongsiatmoy, J. A., 2133  
 Cherny, N. I., 2502  
 Chevreau, C., 61  
 Chiang, P.-H., 1620  
 Chiou, T.-J., 1188  
 Choi, D. H., 1587  
 Chojniak, M. M., 1292  
 Chokkalingam, A. P., 1727  
 Chow, S.-M., 31  
 Christakis, N. A., 2  
 Christensen, B. E., 516  
 Christensen, L., 66  
 Christiani, D. C., 135  
 Chu, D. Z. J., 2266  
 Chu, K. C., 908  
 Chua, D. T. T., 74  
 Chuang, C.-C., 2385  
 Chuang, J.-H., 1444  
 Chun, J. H., 1918  
 Cianfarani, F., 789  
 Cianfrocca, M. E., 918  
 Cimmino, V. M., 2307  
 Cinelli, R., 2440  
 Clark, M. M., 2495  
 Clark, P. E., 955  
 Clarke, C. A., 300  
 Clarke-Pearson, D., 277  
 Clayman, G., 2214, 2322  
 Clemons, M., 542  
 Clingan, P., 320  
 Coassin, M., 1649  
 Coats, C., 504

Coebergh, J.-W. W., 11  
 Cognetti, F., 337  
 Cohen, C. J., 2599  
 Cohen, D. S., 1716  
 Cohen, L. J., 94  
 Cohen, Z. R., 1925  
 Coindre, J.-M., 2700  
 Coit, D. G., 344  
 Coleman, R. E., 1735  
 Collini, P., 571  
 Colombino, M., 1540  
 Colombo, A. L., 315  
 Colombo, M., 529  
 Colucci, P., 900  
 Come, S. E., 229  
 Comegno, A., 2114, 2133  
 Concato, J., 496  
 Contributors to the BAUS Section of  
 Oncology Cancer Registry, 2362  
 Cooksley, C., 1457, 1531  
 Cormack, R. A., 949  
 Cornelison, T. L., 2001, 2044  
 Cortes, J., 81, 437, 522, 888, 1105, 1430,  
 1905, 2483, 2636, 2657  
 Cortes, J. E., 773  
 Cortesi, E., 337, 1707  
 Cossu, A., 1540  
 Costa, S., 315  
 Couanet, D., 155  
 Cousin-Lafay, L., 349  
 Couturier, J., 155  
 Cox, J. D., 1021  
 Cox, L. S., 632, 2495  
 Coze, C., 349  
 Craig, F. E., 300  
 Cramer, A., 2539  
 Crawford, E. D., 1643  
 Crighton, F., 1643  
 Crinò, L., 128  
 Crispino, C., 1707  
 Cristofanilli, M., 900  
 Crum, C. P., 2064  
 Cuenca, R., 1767  
 Culine, S., 61, 745  
 Cullinane, C. A., 1061, 2266  
 Curley, T., 1842  
 Cushing-Haugen, K. L., 1504  
 Cuttica, A., 983  
 Czerniecki, B. J., 468

## D

Dabaja, B. S., 1021  
 d'Abbadie, I., 1232  
 Daikoku, M., 2671  
 Daling, J. R., 1131, 1504  
 Dalton, J., 2232  
 Daly, M. B., 2607  
 D'Amico, A. V., 949  
 d'Amore, E. S. G., 2274  
 Danel-Moore, L., 222  
 Daneshmand, S., 55, 955  
 Danforth, D. N., 697  
 D'Angelica, M., 1689  
 Danson, S., 542

Darwish, S., 128  
 D'Atri, S., 789  
 Dauplat, J., 2599  
 Davidoff, M. S., 2430  
 Davis, R. L., 1243  
 D'Cruz, A. K., 1767  
 De Angelis, V., 128  
 Deapen, D., 1131  
 de Baere, T., 2664  
 De Bernardi, B., 2488  
 De Bonis, M. L., 1540  
 de Camargo, B., 1292  
 de Cássia Braga Ribeiro, K., 1292  
 Deffenbaugh, A. M., 597  
 Degnim, A. C., 2307  
 Dehner, L. P., 2274  
 de Hullu, J. A., 2624  
 DeJager, R., 900  
 DeJesus, Y., 2070  
 de Kraker, J., 389  
 Delaney, G., 1977  
 De Las Casas, L. E., 1898  
 del Carmen, M. G., 590, 1658  
 Delgado, D. J., 2402  
 Delgado, M. A., 2664  
 Deligdisch, L., 2599  
 Dell'Aquila, M., 983  
 Dell'Olio, M., 2393  
 Del Ninno, E., 529  
 Delpassand, E. S., 2028  
 Delprado, W., 2560  
 DeMarco, J., 215  
 De Marinis, F., 128, 337, 1707  
 DeMatteo, R. P., 1689  
 Dembinski, W., 2730  
 Demetri, G. D., 832  
 Denk, H., 703  
 Dershaw, D. D., 377  
 deSa, G. M., 1179  
 D'Esposito, M., 1540  
 Deters, C. A., 1947  
 Deutsch, M., 1362  
 de Vathaire, F., 1309  
 Devesa, S. S., 176  
 de Vijlder, J. J. M., 389  
 de Vries, J., 690  
 Dewhirst, M. W., 277  
 Deyrup, A. T., 805  
 Dezza, L., 2393  
 Dhandapani, D., 1587  
 Diab, S., 597  
 Diaz, E. M., Jr., 2214  
 Diehl, K. M., 2307  
 Dietrich, J., 2678  
 DiGiuseppe, J. A., 300  
 Dijkstra, P. U., 690  
 Dileo, P., 571  
 Di Nicola, M., 983  
 DiPaola, R. S., 1559  
 Di Perri, G., 2440  
 Doglioni, C., 474  
 Dolsma, W., 690  
 Donald, P., 1179  
 Donato, M. F., 529

Dong, Q., 1701  
 Donohue, J. H., 2152  
 Donohue, J. P., 753  
 Dorey, F., 2344  
 Dorey, F. J., 2566  
 Dorfman, R. F., 300  
 dos Santos, L. R. M., 1179  
 Dowd, L., 542  
 Downie, P. A., 397  
 Dralle, H., 712  
 Drezek, R. A., 2015  
 Droz, J.-P., 61  
 Du, W., 1491  
 Duboc, G., 315  
 Dubsky, P., 2547  
 Ducreux, M., 2664  
 Dueckers, G., 1243  
 Duggal, A., 900  
 Dummer, R., 993, 2708  
 Dunn, P., 1206  
 Dunn, R., 1603  
 Dunn, R. L., 269  
 Durivage, H. J., 1559  
 D'Urso, M., 1540  
 Dutcher, J. P., 100  
 Dykes, S. L., 48

## E

Eble, J. N., 1830  
 Edwards, B. K., 1262  
 Egorov, A., 1967  
 Eifel, P., 2052  
 Eiján, A. M., 262  
 Einhorn, L. H., 753  
 Eisenberg, P., 2473  
 Eisma, W. H., 690  
 Elahi, A., 872  
 Ellis, L. M., 720  
 Ellis, M., 229  
 Elmore, J. M., 2329  
 El Nagggar, A. K., 508  
 El-Nagggar, A. K., 2322  
 Elnemr, A., 1394  
 El-Rifai, W., 1547, 2184  
 Elting, L. S., 645, 1531  
 Emoto, M., 1890  
 Endo, K., 932  
 Endou, Y., 1394  
 Entsuah, L. K., 249  
 Epstein, J. I., 2583  
 Erder, M. H., 198, 222  
 Escalante, C., 1039  
 Escudier, B., 61  
 Esmaeli, B., 504  
 Esper, P., 269, 1603  
 Esserman, L., 590  
 Esteve, F. J., 900  
 Estey, E., 2095  
 Estey, E. H., 1681  
 Etzioni, R. D., 496  
 Evans, D. B., 720  
 Evers, K., 918

**F**

- Fabel, K., 2678  
 Fabi, A., 337  
 Fader, A. N., 1658  
 Faderl, S., 437, 522, 773, 1105, 1337, 1430, 2636  
 Fahs, M. C., 2003  
 Failla, C. M., 789  
 Fairve-Finn, C., 542  
 Fan, F., 720  
 Farderl, S., 888  
 Fardig, J., 269, 1603  
 Fasan, M., 2440  
 Faupel, M. L., 2015  
 Faustina, M., 504  
 Fayers, P., 198  
 Fears, C. L., 610  
 Federico, M., 2393  
 Feld, M. S., 2015  
 Feng, Y.-Z., 2207  
 Fenwick, J. D., 41  
 Ferenczy, A., 2015  
 Ferrajoli, A., 773, 1105, 2636, 2657  
 Ferrari, A., 571  
 Ferrell, B., 1061  
 Ferrell, B. R., 2266  
 Feuer, E., 1253  
 Figlin, R. A., 1863, 2566  
 Figueroa-Vadillo, J., 2473  
 Filippa, D. A., 1283  
 Fink, U., 1521  
 Finlay, J. L., 1243  
 Firestone, G. L., 2511  
 Fisher, B., 1362  
 Fisher, D. C., 978  
 Fishman, E. K., 2028, 2039  
 Fitzal, F., 2547  
 Fitzgerald, P. A., 239  
 Fitzpatrick, J. M., 970  
 Fitzpatrick, L. A., 2378  
 Fiumara, P., 310  
 Fizazi, K., 61, 745  
 Fleming, G. F., 1779  
 Fliss, D., 1179  
 Follen, M., 2001, 2015, 2028, 2044  
 Fong, Y., 1689  
 Foot, L., 841  
 Foote, K. D., 1473  
 Foote, R. L., 2378  
 Ford, M. B., 1457  
 Forman, M. R., 1782  
 Fornage, B. D., 2028  
 Förster, G. J., 2257  
 Fossati-Bellani, F., 571  
 Foster, B., 2554  
 Foster, R. S., 753, 1830  
 Fouladi, M., 1243, 2232  
 Foulkes, W. D., 1569  
 Fox, S., 1837  
 Fracasso, P. M., 610  
 Fraker, D. L., 468  
 Franchin, G., 765  
 Franco, E. L., 2064  
 Freedland, S. J., 2344  
 Freedman, G. M., 918  
 Freeman, A., 2362  
 Freireich, E., 81, 888  
 Fridman, M., 222  
 Friedberg, J. W., 978  
 Friedl, J., 2291, 2547  
 Friedman, W. A., 1473  
 Frierson, H. F., Jr., 1547, 2184  
 Fromm, D., 1767  
 Frost, A. R., 187  
 Frost, M. H., 2152  
 Fruehauf, J. P., 1658  
 Fu, K. K., 1497  
 Fuchs, B., 2687  
 Fuchs, C. S., 484  
 Fuchs, H., 406  
 Fujikane, T., 1008  
 Fujino, H., 1822  
 Fujita, Y., 1008  
 Fujiuchi, S., 1008  
 Fukai, Y., 932  
 Fukuchi, M., 932  
 Fukushima, M., 730  
 Fuller, C., 2232

**G**

- Gabriel, C., 970  
 Gadgeel, S., 1491  
 Gajjar, A., 2232  
 Galligioni, E., 474  
 Gamucci, T., 337  
 Gandola, L., 571  
 Gann, P. H., 1870  
 Gannon, B. J., 1114, 2743  
 Gapstur, S. M., 1870  
 Garaventa, A., 2488  
 García-Aguilar, J., 48  
 Garcia-Manero, G., 437, 522, 888, 1105, 1430, 1905, 2636  
 Garden, A. S., 2214, 2322  
 Garside, D., 1870  
 Garzotto, M., 1417  
 Gaskin, D. J., 166  
 Gaspar, N., 349  
 Gatalica, Z., 1947  
 Gaynor, R., 2554  
 Geertzen, J. H. B., 690  
 Geisler, J. P., 2199  
 Genre, D., 1627  
 George, M. J., 1072  
 Gerbing, R. B., 2274  
 Gershenson, D. M., 758  
 Gertler, S., 229  
 Gessner, R., 625  
 Ghadirian, P., 1569  
 Gholam, D., 745  
 Giannarelli, D., 337  
 Gianni, A. M., 983  
 Giannini, C., 356  
 Giantonio, B. J., 1837  
 Gibril, F., 249  
 Giles, F., 81, 406, 888, 1105, 1430, 1905, 2095  
 Giles, F. J., 522, 773, 2636, 2657  
 Gilger, E., 2232  
 Gillenwater, A., 2214  
 Gilles, F. H., 1243  
 Ginsberg, L. E., 2214  
 Giordano, S. H., 1334  
 Giovanazzi, S., 1870  
 Gitlitz, B. J., 1863  
 Giuliano, A. E., 2316  
 Glaser, S. L., 300  
 Gleich, L. L., 1100  
 Glisson, B. S., 2214, 2322  
 Glode, L. M., 1643  
 Glud, E., 66  
 Gnant, M., 2291, 2547  
 Gobbi, P. G., 2393  
 Gobitti, C., 765  
 Godley, P. A., 2592  
 Godwin, A. K., 2607  
 Goel, A., 2091  
 Goepfert, H., 2214  
 Goldschmidt, N., 1239  
 Goldstein, L. J., 918  
 Golli, L., 2664  
 Golovsky, D., 2560  
 Goodheart, M. J., 2199  
 Goodner, S. A., 610  
 Goorin, A. M., 832  
 Gordon, D., 1735  
 Gorlick, R., 832  
 Gornikiewicz, A., 2291  
 Goto, K., 926  
 Gottfredsson, M., 24  
 Govindan, R., 610  
 Goy, A., 310, 1196  
 Grant, B. W., 100  
 Grant, C. S., 2378  
 Grapsas, N. A., 397  
 Grauer, O., 2678  
 Gravis, G., 1627  
 Gravitt, P. E., 814  
 Graw, S. L., 597  
 Greco, F. A., 2192  
 Greenberg, J. S., 508  
 Greenberg, M. D., 814  
 Greenburg, R., 1837  
 Greene, F. L., 2741  
 Greer, B. E., 2052  
 Gregorc, V., 128  
 Gridelli, C., 337, 1707  
 Gridley, G., 1727  
 Griffith, K. A., 854, 2307  
 Grigsby, P. W., 2028  
 Gronchi, A., 571  
 Groothoff, J. W., 690  
 Groshen, S., 955  
 Grunberg, S., 2473  
 Grygiel, J. J., 2560  
 Guillou, L., 1649, 2700  
 Gullane, P., 1179  
 Gulley, M. L., 300  
 Gurevich, L., 1967  
 Guzman, C., 832  
 Gwyn, K., 1055

**H**

- Ha, C. S., 1021  
 Haas, N. B., 1837  
 Habuchi, T., 1635  
 Hachem, R., 292  
 Hachem, R. Y., 1039  
 Hachisuga, T., 1890  
 Hadjimichael, O. C., 814  
 Hafez, K. S., 1169  
 Haffty, B. G., 1587  
 Hafner, C., 2251  
 Hagemeister, F., 310  
 Hahn, R. G., 100  
 Hainsworth, J. D., 2192  
 Hajdenberg, J., 2473  
 Halabi, S., 2592  
 Halbherr, T., 1837  
 Haller, D. G., 484  
 Halmos, G., 1401  
 Halperin, E. C., 1745  
 Halpern, E., 590  
 Hamada, H., 2671  
 Hamilton, T. C., 2607  
 Hampton, G. M., 1547  
 Hampton, J. M., 1749  
 Han, J.-Y., 1918  
 Han, K.-r., 2566  
 Hanbali, F., 1925  
 Hanlon, A. L., 918  
 Hanna, H. A., 1039  
 Hanna, W., 1569  
 Hannoun, L., 2664  
 Hansen, N. M., 2316  
 Hanssens, P. E. J., 1759  
 Hao, S.-P., 2385  
 Hara, I., 1635  
 Hargrave, D., 1014  
 Haring, L. F., 1681  
 Harland, S. J., 2362  
 Harmon, D., 832  
 Harms, W., 1318  
 Harper, J. C., 2184  
 Harris, E. E. R., 1596, 2144  
 Harrison, L. B., 1072  
 Hartley-Asp, B., 1842  
 Hartmann, L. C., 2152  
 Hartmann, O., 349  
 Harvey, D., 1514  
 Hassan, J., 542  
 Hata, J.-i., 2274  
 Hatterman-Zogg, M. A., 2199  
 Hau, P., 2678  
 Haupt, R., 2488  
 Hauschild, A., 993  
 Havrilesky, L. J., 277  
 Hawkins, D. S., 2447  
 Hay, I. D., 356  
 Haydon, R. C., 805  
 Hayes, D. F., 2307  
 Hayes, K., 1905  
 Hayman, J. A., 2177  
 Haynes, A.-M., 2560  
 He, T.-C., 805  
 Healey, J. H., 832  
 Hedrick, E., 1196  
 Hellerstedt, B., 1603  
 Hellman, S., 2351  
 Helton, K., 2232  
 Henshall, S. M., 2560  
 Hensing, T. A., 779  
 Henson, D. E., 908  
 Henze, G., 625  
 Heo, D. S., 2651  
 Herdon, J. E., II, 679  
 Herold, C., 1934  
 Herrero, R., 2064  
 Herrmann, F., 1649  
 Herzog, C., 2457  
 Herzog, T. J., 610  
 Hesdorffer, M., 1942  
 Hickingbottom, B., 144  
 Hidaji, L., 504  
 Hildesheim, A., 814  
 Hilton, L. W., 2070  
 Hinerman, R. W., 2224, 2467  
 Hirose, Y., 2420  
 Hock, B. D., 1681  
 Hoekstra, H. J., 690  
 Hoffman, H. T., 1670  
 Höfler, H., 1521  
 Høgdall, C. K., 66  
 Høgdall, E. V. S., 66  
 Hogg, D., 1947  
 Holland, J. C., 679  
 Holland, J. F., 679  
 Hollema, H., 2624  
 Holmes, R. J., 2199  
 Holzhausen, H.-J., 712  
 Hong, E. K., 1918  
 Hong, W. K., 2214  
 Hooper, D. K., 841  
 Horiuchi, S., 1890  
 Hortobagyi, G. N., 222, 900, 1150  
 Hosokawa, Y., 18  
 Hostein, I., 2700  
 Howell, A., 229, 1735  
 Hsi, R. A., 1767  
 Hsiao, L.-T., 1188  
 Hsieh, H.-H., 1620  
 Hsieh, Y.-C., 1417  
 Hsing, A. W., 1727  
 Hsu, H.-C., 119  
 Hsu, J. C., 2511  
 Hu, T.-H., 1444  
 Huang, C.-C., 1444, 1620  
 Huang, C.-F., 1206  
 Huang, C. I., 135  
 Huang, K.-M., 283  
 Huang, X., 1811  
 Huber, P. E., 1318  
 Huberty, J., 239  
 Hudes, G. R., 1837  
 Hudgens, S., 822  
 Hudson, R. G., 1417  
 Huffman, J. L., 55  
 Hughes, K., 2114, 2133  
 Hughes, K. S., 590  
 Hull, M. C., 2224  
 Humphrey, M. S., 397  
 Hung, R.-L., 283  
 Hunt, D. L., 1243  
 Hunt, K. K., 1150  
 Huo, D., 805  
 Hurd, D., 406  
 Hurt, R. D., 2495  
 Hurwitz, M. D., 949  
 Husain, A. F., 1355  
 Husni, R., 1039  
 Hussein, M. A., 94, 1735  
 Huvos, A. G., 832  
 Hwang, W.-T., 1596, 2144

**I**

- Ianettonni, M., 2177  
 Iannitto, E., 2393  
 Iavarone, M., 529  
 Ifergan, I., 1958  
 Igarashi, M., 110  
 Inazawa, J., 18  
 Inoue, H., 2245  
 Inskip, P. D., 562  
 Inwards, C., 2687  
 Ioannidis, J. P. A., 581  
 Isakov, V. A., 1967  
 Iseki, S., 1002  
 Iselin, C. E., 1649  
 Ishibashi, H., 2671  
 Ishii, G., 926  
 Ishikawa, A., 805  
 Ishikawa, S., 2420  
 Islam, A., 2730  
 Isobe, K., 865  
 Issa, J.-P., 522  
 Issakov, J., 1958  
 Itami, J., 369, 865  
 Ito, A., 1002  
 Ito, H., 865  
 Ito, K., 1411  
 Iwamoto, Y., 1934  
 Iyer, R. B., 2028

**J**

- Jacob, S., 1977  
 Jacobson, K., 1039  
 Jaffe, N., 2457  
 Jakesz, R., 2291, 2547  
 Jansen, K. M., 397  
 Jan, P., 745  
 Janecka, I., 1179  
 Jani, A. B., 2351  
 Janz, N. K., 1811  
 Jarnagin, W. R., 1689  
 Jatoti, I., 894  
 Jauch, K.-W., 2251  
 Jauch, T., 2678  
 Jeha, S., 310, 1337  
 Jennings-Dozier, K., 2070  
 Jensen, R. T., 249  
 Jeong, J.-H., 2257  
 Jett, J. R., 2495  
 Jhingran, A., 2052  
 Jian, B., 187

Jimeno, J., 832  
 Johanning, G. L., 187  
 Johansson, J.-E., 1727  
 Johnson, B. E., 135  
 Johnson, D., 144  
 Johnson, P. J., 288  
 Jolesz, F., 949  
 Jones, B. A., 1299  
 Jones, D., 310  
 Jones, E. L., 277  
 Jones, L. A., 2521  
 Jones, S. E., 229  
 Joshi, V. V., 2274  
 Juffermans, J. H. M., 1759

## K

Kaatz M., 993  
 Kacher, D., 949  
 Kadesky, K. T., 2329  
 Kakinuma, R., 926  
 Kallich, J., 198  
 Kalra, P., 1849  
 Kamata, S., 1179  
 Kamen, B. A., 1559  
 Kamidono, S., 1635  
 Kamineni, A., 1131  
 Kaminski, M., 1735  
 Kamoto, T., 1635  
 Kanai, M., 1089  
 Kanan, A., 949  
 Kanayama, N., 424  
 Kandioler, D., 2547  
 Kane, C. J., 2344  
 Kang, C.-H., 1620  
 Kanitakis, J., 789  
 Kanner, A. A., 1465  
 Kantarjian, H., 81, 292, 1039, 1105, 1430, 1905, 2483  
 Kantarjian, H. M., 86, 437, 522, 888, 1337, 2636, 2657  
 Kao, C.-H., 283  
 Kao, J., 2351  
 Karnell, L. H., 1670  
 Kashima, H., 2207  
 Kashiwagi, B., 1411  
 Kasl, S. V., 1299  
 Kato, H., 932  
 Kato, T., 1635  
 Kattan, M. W., 1842  
 Kawai, H., 110  
 Kawai, K., 1635  
 Kawamura, T., 1394  
 Kawarabayashi, T., 1890  
 Kawauchi, A., 730  
 Kazantseva, I., 1967  
 Keating, M., 81, 522, 2636  
 Keating, M. J., 773, 2657  
 Kelly, W. K., 1842, 2592  
 Kemp, B., 1457  
 Kempf, W., 2708  
 Keohan, M. L., 1942  
 Kerbel, R., 1643  
 Khalifeh, I., 1423  
 Khan, M. A., 2583  
 Khouri, I. F., 2630  
 Kies, M. S., 2214  
 Kikendall, W., 1161  
 Kikuchi, K., 1008  
 Kilic, G., 2554  
 Kim, B. K., 2651  
 Kim, D.-W., 2651  
 Kim, D.-Y., 2651  
 Kim, H., 978  
 Kim, H. T., 100  
 Kim, H. Y., 1918  
 Kim, M. K. H., 841  
 Kim, N. K., 2651  
 Kim, T.-Y., 2651  
 Kim, Y. J., 645  
 Kimura, M., 1089  
 Kinarsky, Y., 1947  
 King, B. L., 1587  
 Kinseth, M. A., 2511  
 Kipnis, V., 1782  
 Kirkwood, J., 100  
 Kitamura, Y., 1002  
 Kjaer, S. K., 66  
 Kleeberg, U. R., 229  
 Klein, C., 597  
 Klein, T., 1417  
 Klencke, B., 239  
 Klimstra, D., 1689  
 Klinkhammer-Schalke, M., 2678  
 Klos, K. S., 1123, 1377  
 Knight, C. A., 222  
 Knopf, B., 993  
 Knopf, K., 1253  
 Knox, W. F., 2539  
 Kobayashi, H., 424  
 Kobayashi, T., 1635  
 Koch, B. B., 1670  
 Koch, H., 2678  
 Koch, H.-J., 993  
 Koch, M. O., 753, 1830  
 Koeller, K., 554  
 Koeneman, K. S., 2329  
 Koga, H., 661  
 Koga, M., 2671  
 Köhler, S. E., 668  
 Koike, H., 1411  
 Kolb, E. A., 832, 2643  
 Koller, C. A., 2657  
 Koma, Y., 1002  
 Kondo, K., 1822, 2420  
 Konishi, I., 2207  
 Konrad, H., 993  
 Konski, A., 1497  
 Kontoyiannis, D., 1039  
 Kontoyiannis, D. P., 86, 292, 773  
 Kooner, R., 2560  
 Kooy, H., 949  
 Kopans, D., 590, 2114  
 Kornblau, S., 81, 888  
 Kornblith, A. B., 679  
 Korsakova, N., 1967  
 Korte, A., 625  
 Kotur, L., 1141  
 Kowalski, L. P., 1179

Krajina, Z., 1767  
 Kraus, D. H., 1179  
 Krempien, B., 1318  
 Krempien, R., 1318  
 Kristensen, G. B., 1880  
 Kroon, B. B. R., 1483  
 Kubishkin, V., 1967  
 Kubota, K., 926  
 Kuester, D., 1934  
 Kulaylat, M. N., 2730  
 Kumar, S., 949  
 Kun, L., 2232  
 Kunkel, M., 2257  
 Kuo, M.-C., 1206  
 Kuo, T.-T., 2385  
 Kurioka, H., 18  
 Kurman, R. J., 814  
 Kuroiwa, T., 110  
 Kurtzberg, J., 94  
 Kurzrock, R., 773, 2410  
 Kuwano, H., 932  
 Kwong, D., 74  
 Kyritsis, A. P., 363, 1021

## L

Lacal, P. M., 789  
 Lacey, J. V., Jr., 814  
 Ladanyi, M., 2643  
 Ladetto, M., 983  
 Lagos, G. K., 363  
 Lai, C.-L., 1206  
 Lai, P.-L., 119  
 Lamers, W. H., 668  
 Lamont, E. B., 2  
 Lampertico, P., 529  
 Land, S. R., 1362  
 Landthaler, M., 2251  
 Lanza, E., 1161  
 Laperriere, N., 1014  
 Lara, J. F., 2105  
 Larson, S., 1842  
 Lau, W.-H., 31  
 Lauderdale, D. S., 2  
 Lautenschläger, C., 712  
 Laverdiere, C., 832  
 Law, L., 1514  
 Law, S. C. K., 31  
 Lawrence, W. D., 1423  
 Lawson, M., 1161  
 Lax, S. F., 703  
 Lazarus, P., 872  
 Lê, M. G., 1232, 1309  
 Leake, C. R., 894  
 Lebret, T., 970  
 Lee, C. J., 18  
 Lee, C.-M., 1444  
 Lee, D. H., 1918  
 Lee, D. W., 1587  
 Lee, H. G., 1918  
 Lee, J.-H., 779  
 Lee, J. S., 1918  
 Lee, K.-W., 2651  
 Lee, M. H., 1587  
 Lee, P., 144



- Lee, P.-H., 119  
 Lee, P. J., 737  
 Lee, S., 144, 1377  
 Lee, S. Y., 1918  
 Lee, W. R., 1987  
 Lei, J., 2576  
 Leibovich, B. C., 2566  
 Leins, A., 2430  
 Lens, M. B., 1355  
 Lentz, S. S., 1664  
 Lenzi, R., 1925  
 Lerner, S., 773, 2657  
 Leung, S., 288  
 Levenback, C. F., 2028  
 Levett, L. M., 1039  
 Levin, V., 1021  
 Levine, P. A., 1179  
 Levine, P. H., 908  
 Levy, C. E., 315  
 Lewis, R. E., 292  
 Li, C. L., 1504  
 Li, Y., 166  
 Liang, D., 1701  
 Liang, D.-C., 1206  
 Liberman, L., 377  
 Libertino, J. A., 737  
 Lichter, A. S., 697  
 Lieskovsky, G., 955  
 Liewehr, D. J., 697  
 Lin, C.-Y., 2385  
 Lin, P., 2457  
 Lin, P.-R., 1444  
 Lin, T.-L., 1206  
 Lindstedt, R., 2430  
 Linetsky, E., 1239  
 Lip, G. Y. H., 1578  
 Lippman, M. E., 697  
 Lippman, S. M., 2214  
 Lipton, A., 962  
 Little, S. A., 1689  
 Litwin, S., 1837  
 Liu, B. C.-S., 2576  
 Liu, D. D., 2214  
 Liu, J.-H., 1188  
 Liu, K., 1870  
 Liu, L.-F., 1444  
 Liu, S.-H., 119  
 Liu, S.-Y., 1444  
 Liu, T., 841  
 Liu, W. B., 720  
 LiVolsi, V. A., 1386  
 Ljung, B.-M., 2170  
 Lloyd, R. V., 2378  
 Lo, Y. M. D., 288  
 Lockwood-Rayermann, S., 2070  
 Logan, H. L., 2467  
 Lolas, K., 363  
 Lopes, L., 949  
 Lu, D. W., 187  
 Lu, K. H., 758  
 Lucas, P. C., 2307  
 Lucenti, A., 474  
 Lui, L. T., 283  
 Luisi, D., 2393  
 Lukens, J. N., 2274  
 Luksch, R., 2488  
 Lumbroso, J., 155  
 Lussan, C., 2700  
 Lustig, R. A., 1767  
 Lyman, G. H., 2402  
 Lynch, H. T., 798, 1569, 1947, 2607  
 Lynch, J. F., 1947  
  
**M**  
 Ma, B., 288  
 Macciocchi, A., 2473  
 Macdonald, J. S., 484  
 Machens, A., 712  
 Mackey, J., 1735  
 MacLennan, G. T., 1830  
 Macquart-Moulin, G., 1627  
 Mader, R. M., 2547  
 Maestri, A., 128  
 Magill, L. A., 2723  
 Magni, M., 983  
 Maiolino, A., 315  
 Maione, P., 337  
 Maisonneuve, P., 474  
 Maki, R. G., 832  
 Maljanian, R., 2335  
 Mallagrino, H., 262  
 Mallard, S., 888  
 Mallick, U. K., 41  
 Malone, J. M., 1423  
 Malone, K. E., 1131, 1504  
 Malpica, A., 758  
 Manda, R., 932  
 Mandel, S. J., 1386  
 Mandelblatt, J. S., 2003  
 Manders, P., 2125  
 Mangini, C., 315  
 Mangold, L. A., 2583  
 Mann, R. B., 300  
 Manning, J. T., Jr., 310  
 Mansourbakht, T., 2664  
 Manzullo, E., 1531  
 Maraninchi, D., 1627  
 Marinone, C., 983  
 Marion, S., 1611  
 Mariotto, A., 1253  
 Markham, M., 2521  
 Markman, M., 215, 885  
 Marshall, J. L., 166  
 Martelli, O., 1707  
 Martellotta, F., 2440  
 Martin, C. G., 645  
 Martin, P. J., 406  
 Martins, C. A., 315  
 Massie, M. J., 679  
 Masters, J. R. W., 2362  
 Mastrangelo, S., 2488  
 Masuda, N., 932  
 Mathew, S., 2715  
 Matsui, H., 1411  
 Matsumoto, T., 2671  
 Matthay, K. K., 155, 239, 2274  
 Mauri, F. A., 474  
 Mauriac, L., 229  
 Mayer, R. J., 484  
 Mazumdar, M., 1611  
 Mazzoni, F., 128  
 McCarthy, W. H., 1223  
 McCauley, M., 978  
 McCowage, G., 1048  
 McDermott, A., 198  
 McGinn, C. J., 1716  
 McGowan, L., 814  
 McKenzie, J. L., 1681  
 McKinnon, J. G., 1223  
 McLaughlin, J. K., 1727  
 McLaughlin, P., 310, 1021  
 McLendon, R. E., 1745  
 McLennan, J., 1569  
 McMahon, L. F., Jr., 1811  
 McMeekin, D. S., 1664  
 McNeese, M., 1457  
 McShane, L., 1161  
 McWilliams, R. R., 356  
 Meazza, C., 571  
 Medeiros, L. J., 310  
 Medina, J., 1905  
 Meeske, K., 2161  
 Mehraein, P., 2430  
 Melancon, C., 1061  
 Mell, L. K., 204  
 Meller, I., 1958  
 Meluch, A. A., 2192  
 Mena, H., 554  
 Mena, M., 2440  
 Menard, C., 697  
 Menck, H. R., 1670  
 Mendenhall, W. M., 1473, 2224, 2467  
 Merchant, T., 2232  
 Merli, F., 2393  
 Meropol, N. J., 166  
 Mertz, M., 679  
 Mery-Mignard, D., 61  
 Metcalfe, K., 1569  
 Meyerhardt, J. A., 484  
 Meyers, C. A., 1021  
 Meyers, P. A., 832  
 Meyskens, F. L., Jr., 2044  
 Mhawech, P., 1649  
 Michaelson, J., 590  
 Michaelson, J. S., 2114, 2133  
 Michon, J., 155  
 Mick, R., 468, 1386  
 Middleman, E. L., 331  
 Middleton, L. P., 1055  
 Middleton, M. R., 542  
 Migliorino, M. R., 128, 337, 1707  
 Mikata, A., 865  
 Miki, T., 730, 1635  
 Million, M., 1273  
 Millenson, M. M., 918  
 Miller, C., 406  
 Miller, D. C., 1169  
 Miller, D. S., 1664  
 Miller, M. C., 2583  
 Miller, S. M., 2009  
 Millot, F., 349  
 Minatel, E., 765

- Minniti, C. J., Jr., 1837  
 Miranda, C. R., 2599  
 Miranda, G., 955  
 Mita, Y., 110  
 Mitchell, S. L., 397  
 Mittlböck, M., 2547  
 Miyakawa, T., 1890  
 Miyamoto, T., 2207  
 Miyata, S., 978  
 Miyazaki, T., 932  
 Miyoshi, T., 1822, 2420  
 Mizutani, Y., 730  
 Mo, V., 508  
 Moinfar, F., 703  
 Moinpour, C. M., 1749  
 Mok, S. C., 2576  
 Molica, S., 2393  
 Molinié, V., 970  
 Möller, M. B., 516  
 Monden, Y., 1822, 2420  
 Monforte, A. D., 2440  
 Montag, A. G., 805  
 Montgomery, L., 2170  
 Montie, J. E., 1169  
 Montroni, M., 2440  
 Montz, F., 2052  
 Montz, F. J., 1658, 2001  
 Moore, C. R., 1830  
 Moore, R., 2114  
 Moore, T. D., 222  
 Moos, P., 841  
 Mora, J., 1283  
 Morandi, X., 618  
 Moreira, V. A., 315  
 Mori, M., 1417  
 Morimoto, Y., 2245  
 Morino, H., 1562  
 Morishita, H., 424  
 Morris, C., 229  
 Morris, C. G., 1473, 2224, 2467  
 Morris, D. L., 320  
 Morris, E. A., 377  
 Morris, J. S., 1716  
 Morris, M., 1842  
 Morris, R., 1423  
 Morrison, W. H., 2214, 2322  
 Morrissey, L. H., 2192  
 Mortel, R., 814  
 Mosharafa, A. A., 753  
 Moskaluk, C. A., 1547, 2184  
 Moskowitz, C., 1196  
 Mosseri, V., 155  
 Motzer, R. J., 1611  
 Moughan, J., 1987  
 Mourits, M. J. E., 2624  
 Mourtzinou, A., 737  
 Mueller, B. A., 1131  
 Mueller, J. D., 1521  
 Mukai, K., 1822  
 Müller, B., 2708  
 Mullineaux, L. G., 597  
 Munakata, S., 1562  
 Mundt, A. J., 204  
 Munkarah, A. R., 1423  
 Munson, N. D., 2378  
 Munzer, C., 349  
 Murayama, S., 369  
 Muscat, J. E., 872  
 Myers, E. R., 2003  
 Myers, J. N., 508  
  
**N**  
 Nadella, P. C., 1141  
 Nagai, K., 926  
 Nagaoka, S., 2671  
 Nagase, A., 1008  
 Nagata, Y., 1377  
 Nagy, A., 1401  
 Nahum, K., 1837  
 Naka, T., 1934  
 Nakajima, M., 932  
 Nakamura, K., 369  
 Nakao, M., 730, 1635  
 Nakata, S., 1411  
 Nakazato, H., 1411  
 Nardone, H. C., 1386  
 Narod, S. A., 1569  
 Nasti, G., 2440  
 Nathanson, S. D., 413  
 Navarria, P., 571  
 Negin, B. P., 344  
 Nelli, F., 128, 1707  
 Neuberg, D., 135, 978  
 Newcomb, P. A., 1749  
 Newman, L. A., 2307  
 Newsham, I., 2232  
 Ng, C. S., 1457  
 Nicolaou, N., 918  
 Niederberger, C. S., 1849  
 Nieweg, O. E., 1483  
 Niho, S., 926  
 Nirelli, L. M., 2495  
 Nishigaki, Y., 1008  
 Nishii, M., 1411  
 Nishikawa, A., 865  
 Nishio, W., 535  
 Nishiwaki, Y., 926  
 Nonomura, N., 1635  
 Noorda, E. M., 1483  
 Nørgaard-Pedersen, B., 66  
 Northcutt, R. C., 2378  
 Norton, J. A., 239  
 Norton, L., 679  
 Novaes, P. E. R. S., 1292  
 Novello, S., 128  
 Noy, A., 1196  
 Nucci, M., 315  
 Nyérén, O., 1727  
  
**O**  
 O'Brien, S., 81, 437, 522, 888, 1105, 1430, 1905, 2095, 2483, 2636  
 O'Brien, S. M., 773, 2657  
 O'Brien, T., 1898  
 O'Byrne, K. J., 542  
 Oda, Y., 1934  
 Odorisio, T., 789  
 Ogawa, K., 369  
 Ogawa, O., 1635  
 Oguchi, M., 865  
 Oh, W. K., 2592  
 Ohata, N., 2245  
 Ohmatsu, H., 926  
 Ohnishi, H., 865  
 Ohsaki, Y., 1008  
 Ohta, Y., 1217  
 Ohtake, N., 1411  
 Ojeaburu, J. V., 249  
 Ojima, H., 932  
 Oka, K., 2207  
 Oka, T., 18  
 Okada, M., 535, 1002  
 Okada, T., 1002  
 Okamoto, H., 1394  
 Okcu, M., 703  
 Oken, M. M., 100  
 Okita, Y., 1002  
 Okoroji, G.-J., 2630  
 Okugi, H., 1411  
 Okuyama, A., 1635  
 O'Leary, M., 949  
 O'Leary, M. P., 2576  
 Oliveira, J. S., 315  
 Oliveria, S. A., 344  
 Olivotto, I. A., 1569  
 Olmi, P., 571  
 Olopade, O., 1569  
 Olsen, C., 554  
 Olson, K., 269, 1603  
 O'Neill, A., 970  
 O'Neill, G. F., 2560  
 Onishi, H., 369  
 Oobayashi, C., 1002  
 Oonk, M. H. M., 2624  
 Orchard, G. E., 2282  
 Orecchia, A., 789  
 Orel, S. G., 468, 1596  
 Oriuchi, N., 932  
 Orme, L. M., 397  
 Orrico, R., 1942  
 Orringer, M. B., 2177  
 Osborne, C. K., 229  
 Osoba, D., 645  
 Ostertag, H., 1934  
 Ott, K., 1521  
 Ou, Y.-H., 119  
 Ouchida, M., 2245  
 Ounpraseuth, S., 144  
 Owen, J. B., 1987  
 Ozaki, T., 2245  
 Ozols, R. F., 2607  
  
**P**  
 Pagano, G., 2440  
 Pai, P.-C., 2385  
 Pairojkul, C., 1438  
 Pajot, C., 349  
 Pakos, E. E., 581  
 Palma, P. D., 474  
 Palmieri, G., 1540  
 Palmieri, M., 1898  
 Pan, C.-X., 1830

- Pan, H.-W., 119  
Pan, M.-H., 283  
Pan, Q., 2643  
Panageas, K. S., 2170  
Panatieri, P., 2335  
Panicek, D. M., 1611  
Pannu, H. K., 2039  
Pantuck, A. J., 2566  
Papadimitrakopoulou, V. A., 2214  
Papadopolous, N., 2693  
Paraguay, N., 315  
Parikh, A. A., 720  
Parisky, Y. R., 590  
Park, S., 2651  
Partin, A. W., 1849, 2583  
Pasik, L., 262  
Paskett, E. D., 2009  
Pasquini, R., 315  
Patchefsky, A. S., 918  
Patel, A. V., 2161  
Patel, R., 1863  
Patel, S. G., 1179  
Patel, S. R., 2693  
Paterson, A. G., 854  
Paterson, R. F., 1830  
Patten, C. A., 2495  
Patton, W. N., 1681  
Paulino, A. F., 1716  
Pawlik, T. M., 1716  
Payne, D., 679  
Payne, H. A., 2362  
Peabody, T. D., 805  
Pearson, P., 2457  
Pecciarini, L., 474  
Pecorelli, S., 1898  
Pedersen, N. T., 516  
Pelmus, M., 2700  
Penalver, M., 2052  
Penault-Llorca, F., 2599  
Peng, S.-Y., 119  
Penson, D. F., 496  
Perfect, J. R., 24  
Perros, P., 41  
Peterman, A., 822  
Peterman, A. H., 779  
Peters, L., 1417  
Peters, W. P., 1491  
Petroni, G., 2184  
Petrucci, E. S., 1457  
Petty, P. M., 2152  
Peuchmaur, M., 2274  
Pfeifer, K., 2678  
Pfeiffer, R., 1161  
Picus, J., 610  
Pienta, K. J., 269, 1603  
Pilat, S. R., 2410  
Pileri, A., 983  
Piller, N. B., 1114, 2743  
Pinkerton, C. R., 1048  
Pitris, C., 2015  
Pizzi, S., 1273  
Pizzitola, M. R., 2488  
Plante, M., 2052  
Podda, M., 2488  
Poggi, M. M., 697  
Politi, D., 765  
Pollack, I. F., 1243  
Pollock, R. E., 1  
Polluri, A., 1179  
Portalone, L., 1707  
Portlock, C., 1196  
Povoski, S. P., 1369  
Powell, S., 2114, 2133  
Powell, S. M., 1547, 2184  
Poynard, T., 2664  
Pradhan, S., 1179  
Pras, E., 2624  
Prasad, R., 2539  
Prayson, R. A., 1465  
Press, M. F., 2161  
Presti, J. C., Jr., 2344  
Prete, A., 2488  
Preti, H. A., 1021  
Price, D., 239  
Pro, B., 1021  
Prosnitz, L. R., 277  
Puduvalli, V. K., 363  
Pui, C.-H., 2715  
Pulliam, J., 406  
Pullman, J., 1080  
**Q**  
Qin, J., 1196, 1283  
Queiroz-Telles, F., 315  
Quek, M. L., 55, 955  
Qui, H., 48  
Quinn, D. L., 955  
**R**  
Raad, I. I., 86, 292, 1039  
Rabel, K., 2070  
Rader, J. S., 610  
Radin, A. I., 100  
Raefsky, E. L., 2192  
Raetz, E. A., 841  
Rafferty, E., 590  
Raghavan, D., 955  
Rai, K. R., 1912  
Raimondi, S. C., 2715  
Rankin, C., 331  
Ranson, M., 542  
Rasiah, K. K., 2560  
Ratschek, M., 703  
Raymond, K., 2457  
Rea, D., 1578  
Redman, B. G., 1603  
Reed, G., 1855  
Reed, W., 1880  
Rees, R., 1716  
Reeves, J. H., 1491  
Regitnig, P., 703  
Reichert, T. E., 2257  
Reichle, A., 2251  
Reilly, R., 1837  
Reiman, T., 1355  
Reinmuth, N., 720  
Reiser, S. J., 1555  
Reitsma, D. J., 1735  
Remington, P. L., 1749  
Reynolds, C., 468  
Riba, M. B., 854  
Richards-Kortum, R., 2015, 2044  
Richardson, M., 1658  
Richie, J. P., 949, 2576  
Richie, J. P., Jr., 872  
Riedel, E., 344  
Rieger-Christ, K. M., 737  
Rietman, J. S., 690  
Riffaud, L., 618  
Rios, M. B., 81, 522, 888, 1105, 1430, 1905, 2636  
Riva, P., 2430  
Rivera, E., 222, 504, 900  
Rivera, G. K., 2715  
Rivero, G. A., 292  
Riveros, M. D., 262  
Roald, B., 2274  
Roberts, D., 508  
Robertson, J. F. R., 229  
Robinson, J. M., 397  
Robinson, R. A., 1670  
Robson, M., 2170  
Roche, J. K., 2184  
Rock, M. G., 2687  
Rodriguez, L. C., 610  
Rodriguez, M. A., 310  
Roeske, J. C., 204  
Roessner, A., 1934  
Roka, S., 2291, 2547  
Roland, I. H., 2607  
Rolland, F., 61  
Rolston, K. V. I., 86, 1039  
Romaguera, J., 310  
Roman, J. J., 1898  
Ronchi, G., 529  
Rosace, M., 983  
Rosato, E. F., 468  
Rosato, J., 949  
Rose, B., 239  
Rose, P. G., 2052  
Rosen, L. S., 1735  
Rosenberg, S., 679  
Rosenthal, D. I., 2322  
Rosenwald, I. B., 1080  
Ross, L. S., 1849  
Rossoff, L., 1912  
Rothenberger, D. A., 48  
Roumen, R. M. H., 11  
Roy, K., 2044  
Roy, M., 2052  
Royce, M., 900  
Rubenstein, E. B., 645, 1531  
Rubino, C., 1309  
Rudas, M., 2547  
Ruiz-Casado, A., 832  
Rulyak, S. J., 798  
Runowicz, C. D., 2064  
Ruo, L., 1689  
Rushing, E. J., 554  
Russell-Jones, R., 2282  
Rust, S., 590  
Rutka, J. T., 1014

Rutten, H. J. T., 11  
 Rybicki, L. A., 94, 1465  
 Ryu, J. K., 1514

# S

- Sabel, M. S., 2307  
 Saeki, N., 369  
 Sagalowsky, A. I., 2329  
 Sahin, A., 1055  
 Sahin, A. A., 1150  
 Sakamoto, T., 535  
 Sakiyama, S., 1822, 2420  
 Sakurai, S., 1394  
 Salem, N., 1627  
 Saliba, R. M., 2630  
 Salner, A., 2335  
 Samii, A., 1934  
 Samulski, T. V., 277  
 Sanchez, J. D., 1863  
 Sandella, J., 2070  
 Sanders, G. D., 2003  
 Sandes, E. O., 262  
 Sandlund, J. T., 2715  
 Sandstad, B., 1880  
 Santi, M., 554  
 Santin, A. D., 1898  
 Santoro, E. J., 2105  
 Sanz, M. A., 1048  
 Sapp, A. L., 1749  
 Sardi, A., 590  
 Sartor, G., 765  
 Sasada, T., 1089  
 Sasaki, T., 1394  
 Sastry, J., 2044  
 Sata, M., 2671  
 Satija, S., 2114  
 Satoru, H., 2177  
 Satta, M. P., 1540  
 Savas, L., 1080  
 Sawaya, R., 1925  
 Sbach, A., 2070  
 Scagliotti, G. V., 128  
 Schaid, D. J., 2152  
 Schally, A. V., 1401  
 Schantz, S. P., 872  
 Schatzkin, A., 1161  
 Schell, M. J., 779  
 Schell, W. A., 24  
 Scher, H. I., 1842  
 Schietroma, C., 789  
 Schlaier, J., 2678  
 Schlosshauer, P. W., 2599  
 Schlumberger, M., 1309  
 Schmandt, R. E., 758  
 Schnall, M., 468  
 Schnater, J. M., 668  
 Schommer, D., 2214  
 Schover, L., 2009  
 Schramm, V., 1179  
 Schroeder, D. R., 2495  
 Schuierer, G., 2678  
 Schulmacher, C., 1521  
 Schulman, K. A., 166  
 Schultz, D., 949  
 Schwartz, A. G., 603  
 Schwartz, J. L., 854  
 Schwartz, L., 1842  
 Schwartz, L. H., 1611  
 Schwartz, P. E., 814  
 Sciuto, L. C., 697  
 Scudder, S. A., 1514  
 Seabrooke, L. F., 1021  
 Seaman, J., 962  
 Seaman, J. J., 1735  
 Seeger, K., 625  
 Seeger, R., 841  
 Sehdev, A. E. S., 1658  
 Seifert, B., 2708  
 Seletti, C., 529  
 Sellers, T. A., 2152  
 Selvaggi, F. C. G., 128  
 Selwyn, B. J., 1457  
 Serment, G., 1627  
 Severi, G., 2488  
 Seyednejad, F., 2144  
 Sgroi, D., 2133  
 Shah, J. P., 1179  
 Shalom, E., 1239  
 Sham, J. S. T., 74  
 Shamsaldin, A., 1309  
 Shan, J., 81, 522, 888, 1105, 1430, 2636  
 Shapiro, C. L., 1141  
 Shapiro, R. M., 1863  
 Shasha, D., 1072  
 Shaw, J., 597  
 Sheehan, J. K., 1438  
 Shen, Y., 1681  
 Sherman, M. E., 176  
 Sheu, J.-C., 119  
 Shi, D., 1123  
 Shiftan, T. L., 222  
 Shih, H.-C., 2207  
 Shih, L.-Y., 1206  
 Shikama, N., 369, 865  
 Shimada, H., 2274  
 Shimizu, K., 2245  
 Shimizu, T., 1008  
 Shin, D. B., 1587  
 Shin, E. H., 1918  
 Shiozawa, T., 2207  
 Shiue, Y.-L., 1620  
 Shroyer, K. R., 2064  
 Shu, K., 1620  
 Shurtleff, S. A., 2715  
 Shvartsman, H., 758  
 Siddiqui, A. K., 1912  
 Siegal, T., 1239  
 Sieracki, B., 1514  
 Siewert, J. R., 1521  
 Sigurdson, A. J., 1457  
 Silverman, M., 737  
 Silverstein, M., 2114, 2133  
 Sim, F. H., 2687  
 Simões, B. P., 315  
 Simon, M. S., 1131  
 Singh, B., 1179  
 Singhal, A., 1767  
 Singletary, S. E., 2741  
 Sison, C. P., 1912  
 Sitarik, M., 597  
 Skinner, D. G., 955  
 Skubitz, A. P. N., 1029  
 Skubitz, K. M., 1029  
 Slater, E., 166  
 Slezak, J. M., 2152  
 Sloan, A. E., 603  
 Slovin, S., 1842  
 Small, E. J., 2592  
 Smith, A., 1611  
 Smith, B., 2114, 2133  
 Smith, D. C., 269, 1603  
 Smith, D. D., 2266  
 Smith, J., 144  
 Smith, R. B., 1670  
 Smith, S. L., 697, 1061  
 Smith, T. L., 1123  
 Snively, J., 144  
 Snyder, M. L., 2307  
 Snyderman, C., 1179  
 Sobin, L. H., 2741  
 Socinski, M. A., 779, 822  
 Sogawa, K., 1822  
 Sohda, M., 932  
 Soler-Vila, H., 1299  
 Solin, L. J., 1596, 2144  
 Solit, D. B., 1842  
 Solza, C., 315  
 Sondak, V. K., 1716  
 Sonet, A., 1048  
 Sonis, S. T., 406  
 Sood, A. K., 2199  
 Soper, J., 277  
 Souza, C. A., 315  
 Span, P. N., 2125  
 Spielmann, M., 1232  
 Spigos, D. G., 1369  
 Spittle, M. F., 2282  
 Spitz, F. R., 468  
 Spitz, M. R., 1457, 1701  
 Sporn, E., 2547  
 Staff, I., 2335  
 Stafford, S. L., 356  
 Stasi, R., 1786  
 Steger, G., 2291  
 Stehman, F. B., 2052  
 Stein, J. P., 955  
 Steinberg, S. M., 697  
 Steinherz, P. G., 2643  
 Steinhorst, F., 1292  
 Steis, R. G., 2192  
 Stelitano, C., 2393  
 Stenbrecher, A., 2678  
 Stephens, D. L., 2070  
 Stewart, A., 1169  
 Stewart, J. A., 100  
 Stift, A., 2291  
 Stoeltzing, O., 720  
 Stonelake, P. S., 1578  
 Storthz, K. A., 2044  
 Stouse, T. B., 212  
 Stout, R., 542  
 Stram, D. O., 2274

Straus, D. J., 1196  
 Strazzullo, M., 1540  
 Stricker, P. D., 2560  
 Stross, J. K., 1811  
 Suda, T., 110  
 Suga, M., 926  
 Sugiyama, K., 1394  
 Suki, D., 1925  
 Sulmasy, D. P., 166  
 Summerhayes, I. C., 737  
 Sun, C., 758  
 Sun, P., 1569  
 Supko, J. G., 832  
 Sutherland, R. L., 2560  
 Suzuki, K., 1411  
 Suzuki, M., 424  
 Swan, J., 1262  
 Swanson, C. A., 814  
 Sweeney, C. J., 1830  
 Sweep, C. (F.) G. J., 2125  
 Swensen, S. J., 2495  
 Syed, S., 2088  
 Sykes, D. E., 2730  
 Szepeshazi, K., 1401

# T

Tagawa, S. T., 144  
 Taghian, A., 2114, 2133  
 Tai, M. H., 1444  
 Taieb, J., 2664  
 Takabayashi, A., 1089  
 Takahashi, Y., 1822, 2420  
 Takasawa, S., 1394  
 Takatsuka, Y., 1562  
 Takita, J., 932  
 Takizawa, H., 2420  
 Takvorian, T., 978  
 Talamini, R., 765, 2440  
 Talbot, S. M., 331, 1942  
 Talpaz, M., 81, 437, 522, 888, 1105, 1430, 1905, 2410, 2483, 2636  
 Tamura, M., 1217  
 Tan, B. R., 610  
 Tanabe, K. K., 2133  
 Tanaka, Y., 424  
 Tanda, F., 1540  
 Tannehill, S. P., 2224  
 Tarella, C., 983  
 Tariq, N., 1014  
 Taub, R. N., 213, 331, 1942  
 Taucher, S., 2547  
 Tavassoli, F. A., 703  
 Taylor, K. L., 632  
 Tchekmedyan, N. S., 198  
 Tedeschi, P. J., 1811  
 Tempany, C. M., 949  
 Templeton, S. F., 2105  
 Tepsiri, N., 1438  
 Terao, T., 424  
 Tercyak, K. P., 632  
 Terrier-Lacombe, M.-J., 745  
 Terris, M. K., 2344  
 Teruya-Feldstein, J., 1196  
 Terzoli, E., 1786

Thanh, P. N., 712  
 Thatcher, N., 542  
 The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group, 1802  
 Thedford, K., 1870  
 Theodore, C., 745  
 Theriault, R., 1055  
 Thomas, D., 81, 888  
 Thomas, D. A., 773, 2657  
 Thompson, G. B., 2378  
 Thompson, J. F., 1223  
 Thompson, S., 262  
 Thornby, J., 292  
 Thornton, A., 758  
 Tiegs, R. D., 2378  
 Tiguaud, J.-M., 2664  
 Tirelli, U., 2440  
 Tjan-Heijnen, V. C. G., 2125  
 Togami, J., 1849  
 Toita, T., 369  
 Tonato, M., 128  
 Topulos, G. P., 949  
 Torosian, M. H., 918  
 Torres, H. A., 86, 292  
 Tortolero-Luna, G., 2064  
 Trabasso, P., 315  
 Trask, P. C., 854  
 Treggiari, S., 1707  
 Treiber, M., 1318  
 Tremont-Lukats, I. W., 363  
 Trent, J. C., 2693  
 Trentham-Dietz, A., 1749  
 Trimble, E. L., 2001, 2075  
 Trovò, M. G., 765  
 Troxel, A. B., 1942  
 Tsang, N.-M., 2385  
 Tsao, A. S., 2483  
 Tseng, C.-C., 940  
 Tseng, C.-K., 2385  
 Tsubota, N., 535, 1002  
 Tsujioka, H., 1890  
 Tsukada, K., 932  
 Tsuneyoshi, M., 1934  
 Tsuyuguchi, M., 2420  
 Tsybrovsky, O., 703  
 Tu, S.-M., 504  
 Tubbs, R. R., 1465  
 Tuncali, K., 949  
 Tung, N., 1569  
 Turić, M., 1767  
 Turner, J. J., 2560

# U

Uchihara, H., 2420  
 Uchikawa, J., 2207  
 Uchino, K., 535, 1002  
 Ueno, N., 865  
 Ulbright, T. M., 753, 1830  
 Ulrich, W., 2678  
 Umehara, N., 2245  
 Uno, T., 369, 865  
 Urba, S. G., 2177  
 Urošević, M., 2708

# V

Vaccher, E., 765, 2440  
 Valentine, K., 949  
 Valenzuela, R. G., 2687  
 Valero, V., 504, 900  
 Valteau-Couanet, D., 155  
 van Coevorden, F., 1483  
 Van den Berg, H., 1048  
 van der Sangen, M. J. C., 11  
 van der Zee, A. G. J., 2624  
 van der Zee, J., 1759  
 van Eck, B. L. F., 389  
 Van Harrison, R., 1811  
 van Heerden, J. A., 2378  
 Van Horn, L., 1870  
 van Putten, W. L. J., 1759  
 van Rhoo, G. C., 1759  
 van Santen, H. M., 389  
 van Slooten, G. W., 1483  
 Van Veldhuizen, P. J., 1855  
 Varon, D., 1239  
 Vaz, J., 315  
 Velilla, R. E., 2105  
 Veltri, R. W., 2583  
 Venkatraman, E., 2368  
 Vergote, I., 229  
 Veronese, S., 474  
 Verstovsek, S., 1430, 2636  
 Vickers, A. J., 2723  
 Viens, P., 1627  
 Villaret, D. B., 2224  
 Viscardi, E., 2488  
 Vogelbaum, M. A., 1465  
 Vogelzang, N. J., 2592  
 Vogl, T. J., 1767  
 Vogt, T., 2251  
 Voltarelli, J. C., 315  
 von Mehren, M., 918  
 von Schweinitz, D., 668  
 Voogd, A. C., 11  
 Vredenburg, J. J., 24  
 Vreugdenhil, G., 11  
 Vrouwenraets, B. C., 1483  
 Vulsma, T., 389

# W

Wada, H., 730  
 Wagman, L. D., 2266  
 Wagman, R., 1689  
 Wagner, B. W., 1401  
 Wagner, W., 2257  
 Waguri, N., 110  
 Wain, E. M., 2282  
 Wakayama, T., 1002  
 Wakely, P. E., 1369  
 Walker, J. L., 2044  
 Walsh, P. C., 2583  
 Wang, E. S., 1196  
 Wang, L., 1611  
 Wang, P.-N., 1206  
 Wang, S., 1080  
 Wang, W.-S., 1188  
 Wang, Y., 1701  
 Wang, Y.-H., 283



Wang-Johanning, F., 187  
 Wannemacher, M., 1318  
 Wargovich, M., 1161  
 Warren, J., 1253  
 Watson, R. W. G., 970  
 Weaver, D. L., 2083  
 Weber, B., 1569  
 Weber, J. S., 144  
 Weber, R. W., 1386  
 Webster, A., 229  
 Webster, K., 822  
 Wei, J. T., 1169  
 Wei, J. Y., 135  
 Wei, W. I., 1179  
 Weightman, D. R., 41  
 Weinberg, J. S., 1925  
 Weinfurt, K. P., 166  
 Weinstein, M. H., 2576  
 Weis, S., 2430  
 Weisburger, J. H., 2734  
 Weiss, N. S., 1504  
 Weiss, R. B., 679  
 Wenzel, L. B., 2009  
 Werner, C., 2592  
 Werning, J. W., 2224  
 Wexler, L., 832  
 Weybora, W., 703  
 Wharton, J. T., 2052  
 Whimbey, E. E., 1039  
 White, K., 888  
 Whiteside, T. L., 2257  
 Whitman, G. J., 1150  
 Whittaker, S. J., 2282  
 Whn, T., 1514  
 Widmark, C., 2070  
 Wieand, H. S., 1362  
 Wierda, W., 1105, 2636  
 Wierda, W. G., 2657  
 Wiernik, P., 100  
 Wilder, R. B., 1021  
 Williamson, S., 1855  
 Wilson, J., 1141  
 Wingard, J. R., 406  
 Wingate, P., 679  
 Wismeth, C., 2678  
 Woda, B., 1080  
 Wolf, J., 2075  
 Wolf, J. K., 2064  
 Wolfe, R. A., 1811  
 Wollina, U., 993

Wollner, N., 1283  
 Wolmark, N., 1362  
 Wong, K., 554  
 Wongkham, C., 1438  
 Wongkham, S., 1438  
 Wood, M. E., 597  
 Woodard, S., 1141  
 Woods, J. E., 2152  
 Wu, A. H., 940  
 Wu, H. H., 2410  
 Wu, J.-H., 1206  
 Wu, S., 625  
 Wu, T.-C., 2064  
 Wu, X., 1701  
 Wymenga, A. N. M., 2624

## X

Xu, J., 24  
 Xu, X.-X., 2607  
 Xu, Y., 2576

## Y

Yaghubian, R., 2291  
 Yamakawa, T., 424  
 Yamamoto, H., 1394  
 Yamanaka, H., 1411  
 Yamazaki, Y., 1008  
 Yan, D. B., 320  
 Yang, D.-H., 2607  
 Yang, J. W., 1620  
 Yang, M.-H., 1188  
 Yang, W., 1123, 1377  
 Yang, W.-L., 2607  
 Yang, Y., 1123, 1681  
 Yano, K., 2671  
 Yano, M., 2671  
 Yanssens, T. L., 1369  
 Yao, J., 1123  
 Yardley, D., 2554  
 Yasko, A. W., 2457  
 Yasui, K., 18  
 Yates, A. J., 1243  
 Yatsushashi, H., 2671  
 Yau, S., 31  
 Ye, B., 2576  
 Yen, C., 2554  
 Yen, C.-C., 1188  
 Yen, R.-F., 283  
 Yeslow, G., 1837  
 Yoh, K., 926

Yokota, T., 110  
 Yonemura, Y., 1394  
 Yoon, S. M., 1918  
 Yoon, S.-S., 2651  
 Yoshida, A., 2245  
 Yoshida, O., 730  
 Yoshida, Y., 1089  
 Yoshii, Y., 369  
 Yoshizawa, K., 2420  
 Younes, A., 310, 458  
 Young, S. M., 2105  
 Yu, D., 1123, 1377  
 Yu, T.-J., 1620  
 Yu, X. Q., 1223  
 Yun, T., 2651  
 Yung, W. K. A., 1021

## Z

Zacharin, M. R., 397  
 Zagha, R. M., 737  
 Zagrodnik, B., 2708  
 Zahurak, M. L., 1658  
 Zaika, A., 1547  
 Zallio, F., 983  
 Zambruno, G., 789  
 Zamora, R., 2473  
 Zee, B., 288  
 Zelefsky, M. J., 1987  
 Zelenetz, A. D., 1196  
 Zeliadt, S. B., 496  
 Zhang, C., 679  
 Zhang, J., 2511  
 Zhang, K., 1701  
 Zhang, L., 1377  
 Zhang, S., 1830  
 Zhao, C., 18  
 Zhen, W., 1670  
 Zheng, M., 962  
 Zheng, Y., 2576  
 Zheng, Z., 872  
 Zhou, X., 1123, 1377  
 Zhou, Y., 2715  
 Ziober, A. F., 1386  
 Ziober, B. L., 1386  
 Zion, S. M., 2152  
 Zommer, A., 2291  
 Zuckerman, E. L., 679  
 Zulfiqar, M., 1855